0001213900-23-043104.txt : 20230525 0001213900-23-043104.hdr.sgml : 20230525 20230525163117 ACCESSION NUMBER: 0001213900-23-043104 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 62 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230525 DATE AS OF CHANGE: 20230525 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Raphael Pharmaceutical Inc. CENTRAL INDEX KEY: 0001415397 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 260204284 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-53002 FILM NUMBER: 23961231 BUSINESS ADDRESS: STREET 1: SUITE 105 - 5348 VEGAS DR. CITY: LAS VEGAS STATE: NV ZIP: 89108 BUSINESS PHONE: 702-442-1166 MAIL ADDRESS: STREET 1: SUITE 105 - 5348 VEGAS DR. CITY: LAS VEGAS STATE: NV ZIP: 89108 FORMER COMPANY: FORMER CONFORMED NAME: Easy Energy Inc DATE OF NAME CHANGE: 20071017 10-K/A 1 f10k2022a1_raphaelpharma.htm AMENDMENT NO. 1 TO FORM 10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K/A

(Amendment No. 1)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File No. 000-53002

Raphael Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Nevada

26-0204284

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer

Identification No.)

4 Lui Paster

Tel Aviv-Jaffa, Israel 6803605

(Address of Principal Executive Offices)

Registrant’s Telephone Number: (972) 52-775-5072

Securities Registered pursuant to Section 12(b) of the Act:

NONE

Securities Registered pursuant to Section 12(g) of the Act:

Common Stock, $0.01 par value

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,’’ “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filed	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of the last business day of the registrant’s most recently completed second fiscal quarter the registrant did not have any publicly traded securities.

As of May 25, 2023, there were 16,135,790 shares of common stock, par value $0.01, or Common Stock, of the registrant issued and outstanding.

Documents Incorporated By Reference: None.

EXPLANATORY NOTE

Raphael Pharmaceutics Inc. (the “Company”) is filing this Amendment No. 1 (the “Amendment”) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 24, 2023 (the “Original Filing”), for the sole purpose of amending and restating the disclosure provided in Item 9 of Part II and including the audit letter of Brightman Almagor Zohar & Co., a firm in the Deloitte global network (the “Former Auditor”), in Item 15 of Part IV, which were inadvertently omitted from the Original Filing.

In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the certifications pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 have been re-executed as of the date of, and are re-filed as part of, this Amendment as Exhibits 12.1, 12.2, 13.1 and 13.2.

Other than expressly set forth herein, this Amendment does not reflect events occurring after the date of the filing of the Original Filing or modify or update any of the other disclosures contained therein in any way.

TABLE OF CONTENTS

Item No.	Description	Page
	PART II	1
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	1
	PART IV	2

Item 15.	Exhibits and Financial Statement Schedules	2
Signatures		4

PART II

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

As previously disclosed by the Company on a Form 8-K filed with the Securities and Exchange Commission on July 7, 2022, on July 5, 2022, the board of directors of the Company dismissed Brightman Almagor Zohar & Co., a firm in the Deloitte global network (the “Former Auditor”), as the Company’s independent registered public accounting firm, effective July 5, 2022.

Except for an explanatory paragraph in the Former Auditor’s audit report regarding substantial doubt about the Company’s ability to continue as a going concern, the audit reports of the Former Auditor on the Company’s financial statements for the fiscal years ended December 31, 2021 and 2020 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

During the fiscal years ended December 31, 2021 and 2020, and the subsequent interim period through July 5, 2022, there were (i) no “disagreements” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and the Former Auditor on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of the Former Auditor, would have caused the Former Auditor to make reference to the subject matter of the disagreement in its reports on the Company’s financial statements and (ii) no “reportable events” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K and the related instructions).

The Company provided the Former Auditor with a copy of the foregoing disclosures and requested that the Former Auditor furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made herein and, if not, stating the respects in which it does not agree. A copy of the letter provided by the Former Auditor, dated July 7, 2022, is filed as Exhibit 16.1 to our Form 8-K filed on July 7, 2022.

On July 5, 2022, the board of directors of the Company approved the engagement of Weinstein International. C.P.A. (the “New Auditor”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022, effective upon the effectiveness of the dismissal of the Former Auditor. During the fiscal years ended December 31, 2021 and 2020, and the subsequent interim period through July 5, 2022, neither the Company, nor anyone on its behalf, consulted the New Auditor regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report or oral advice was provided to the Company by the New Auditor that the New Auditor concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue or (ii) any matter that was the subject of a “disagreement” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

PART IV

Item 15. Exhibits, Financial Statement Schedules.

(a) Financial Statements.

RAPHAEL PHARMACEUTICAL INC. AND ITS SUBSIDIARY

CONSOLIDATED FINANCIAL STATEMENTS

AS OF DECEMBER 31, 2022

U.S. DOLLARS IN THOUSANDS

INDEX

	Page

Report of independent Registered Public Accounting Firm (PCAOB ID No. 6629)	F-2

Report of independent Registered Public Accounting Firm (PCAOB ID No. 1197)	F-4

Consolidated Balance Sheets	F-6

Consolidated Statements of Comprehensive Loss	F-7

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)	F-8

Consolidated Statements of Cash Flows	F-9

Notes to Consolidated Financial Statements	F-10 - F-23

- - - - - - - - - - -

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of Raphael Pharmaceutical Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Raphael Pharmaceutical Inc. and its subsidiary (the “Company”) as of December 31, 2022, the related consolidated statements of comprehensive loss, changes in stockholders’ equity (deficit) and cash flows for the year ended December 31, 2022, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and the results of its operations and its cash flows for the year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1b to the financial statements, the Company’s lack of revenues and accumulated operating losses raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1b. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Previous Auditor

This is the first year for which we have served as auditor. The previous year was audited by a different auditor whose permission we have received to serve as the current auditor.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

	A Member Of The
www.dwacc.com	International Accounting Group

A: Ha-Rekhev St 8, Tel Aviv-Yafo IL | US Number: 1-661-466-2466 | Local: +972-58–6886666 | E: i@dwacc.com

F-2

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Issuance of share capital and warrants - Changes in Ordinary Share Capital– Refer to Note 7 to the Consolidated Financial Statements

Critical Audit Matter Description

During the year ended December 31, 2022, the Company raised equity in the aggregate amount of $896 thousands, through equity transactions, by issuing shares and warrants.

We deemed our audit over the issuance of share capital and warrants as a critical audit matter because of the magnitude of the transactions and the increased extent of auditing effort, in relation to the audit as a whole, to evaluate management’s classification of the equity transactions.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to the issuance of share capital and warrants transactions included the following, among others:

●

We read the agreements and analyzed the terms of the Company’s equity transactions.

●

We evaluated management’s interpretation and application of the relevant accounting guidance in relation to the appropriateness of the equity classification of warrants issued in these transactions.

●

We agreed the consideration received from the transactions to the respective bank statements.

●

We compared the shares issued and outstanding to the confirmation obtained directly from the transfer agent.

/s/ Weinstein International CPA

Weinstein International CPA

Tel Aviv, Israel

March 23, 2023

We have served as the Company’s auditor since 2022.

www.dwacc.com

A Member Of The

International Accounting Group

A: Ha-Rekhev St 8, Tel Aviv-Yafo IL | US Number: 1-661-466-2466 | Local: +972-58–6886666 | E: i@dwacc.com

F-3

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of Raphael Pharmaceutical Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Raphael Pharmaceutical Inc. and its subsidiary (the “Company”) as of December 31, 2021 and 2020, the related consolidated statements of comprehensive loss, changes in shareholders’ deficit and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020 and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

Going Concern

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

F-4

Critical Audit Matter

Changes in Ordinary Share Capital – refer to note 7 to the consolidated financial statements

Critical Audit Matter Description

During the year ended December 31, 2021, the Company raised equity in the aggregate amount of $1,290 thousands, through equity transactions, by issuing shares and warrants.

We deemed our audit over the allocation, classification and accuracy of equity transactions as challenging from a perspective of audit effort in comparison to our audit as a whole, because of the amount of equity transactions and due to the magnitude of total amounts raised. As such, we believe this represents a critical audit matter.

How the Critical Audit Matter Was Addressed in the Audit

Our audit procedures related to equity transactions included the following, among others:

●

We read the agreements and analyzed the terms of the Company’s equity transactions.

●

We evaluated the interpretation and application of the relevant accounting guidance in relation to the appropriateness of the equity classification of warrants issued in these transactions.

●

We agreed the consideration received from the transactions to the respective bank statements.

●

We compared the shares issued and outstanding to the confirmation obtained directly from the transfer agent.

/s/ Brightman Almagor Zohar & Co.

Certified Public Accountants

A Firm in the Deloitte Global Network

Tel Aviv, Israel

March 30, 2022

We have served as the Company’s auditor since 2021.

F-5

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS

U.S dollars in thousands (except for share and per share data)

	Note		As of December 31,
			2022			2021

Assets
Current assets:
Cash and cash equivalents			$	288		$	153
Other current assets		3		43			269

Total current assets				331			422

Non-Current assets:

Fixed asset, net				2			-

Total assets			$	333		$	422

Liabilities and stockholders’ equity (deficit)

Current liabilities:
Other accounts payable and accrued expenses		4		224			272
Payable to related party				3			22

Total current liabilities				227			294

Stockholders’ equity (deficit):

Common stock, $0.01 par value:

Authorized: 21,020,560 shares;

Issued and outstanding: 15,624,040 and 12,970,540 as of December 31, 2022 and December 31, 2021, respectively				157			130
Additional paid-in capital				5,975			2,665
Accumulated deficit				(6,026	)		(2,667	)

Total stockholders’ equity				106			128

Total liabilities and stockholders’ equity			$	333		$	422

The accompanying notes are an integral part of the condensed consolidated financial statements.

F-6

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S dollars in thousands (except for share and per share data)

	Note		For the year ended December 31,
			2022		2021
Research and development expenses		10a	$	1,178	$	776

General and administrative expenses		10b		2,139		853

Operating loss				3,317		1,629

Total financial expense, net		10c		41		(4	)

Net loss and comprehensive loss				3,358		1,625

Basic and diluted net loss per share				0.23		0.15

Weighted average number of common shares used in computing basic and diluted net loss per share				14,341,518		11,171,704

The accompanying notes are an integral part of the condensed consolidated financial statements.

F-7

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CHANGES STOCKHOLDERS’ IN EQUITY (DEFICIT)

U.S dollars in thousands (except for share and per share data)

	Common stock				Additional paid-in		Accumulated			Total
	Number		Amount		capital		deficit			equity

Balance as of January 1, 2022		12,970,540	$	130	$	2,666	$	(2,668	)	$	128

Issuance of common stock and warrants		831,000		8		885		-			893

Issuance of common stock in exchange for services		1,822,500		19		2,424		-			2,443

Net loss		-		-		-		(3,358	)		(3,358	)

Balance as of December 31, 2022		15,624,040	$	157	$	5,975	$	(6,026	)	$	106

	Common stock				Additional paid-in		Accumulated			Total
	Number		Amount		capital		deficit			equity

Balance as of January 1, 2021 (**)		9,459,253	$	95	$	905	$	(1,043	)	$	(43	)

Issuance of common stock and warrants		2,460,259		25		1,265		-			1,290

Effect of reverse recapitalization transaction (Notes 1a and 7b)		1,051,028		10		496		-			506

Net loss		-		-		-		(1,625	)		(1,625	)

Balance as of December 31, 2021		12,970,540	$	130	$	2,666	$	(2,668	)	$	128

(*)	Represents amount less than $1

(**)	Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the reverse recapitalization transaction and to reflect adjustment to the share par value (refer to Note 1a).

The accompanying notes are an integral part of the consolidated financial statements.

F-8

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS

U.S dollars in thousands (except for share and per share data)

	Year Ended December 31,
	2022			2021
Cash flows from operating activities

Net loss	$	(3,358	)	$	(1,625	)
Adjustments to reconcile net loss to net cash used in operating activities:

Share-based payment in exchange for services		2,290			-
Changes in:
Other current assets		226			(41	)
Related parties		(19	)		13
Other accounts payables and accrued expenses		102			234

Net cash used in operating activities		(759	)		(1,419	)

Cash flows from investing activities

Purchase of fixed assets		(2	)		-

Net cash provided by investing activities		(2	)		-

Cash flows from financing activities

Receipt of a loan		-			174
Proceeds from issuance of common stock and warrants		896			1,290
Cash acquired in the reverse recapitalization (*)		-			13
Net cash provided by financing activities		896			1,477

Change in cash and cash equivalents		135			58
Cash and cash equivalents at the beginning of the year		153			95

Cash and cash equivalents at the end of the year	$	288		$	153

Non cash supplement
Issuance of shares for past services (Note 7e)	$	150		$	-
Non cash issuance costs (Note 7g)	$	70		$	102

(*) Cash acquired in the reverse recapitalization:
Current assets (excluding cash and cash equivalents)		-			(531	)
Current liabilities		-			38
Reverse recapitalization effect on equity		-			506
Cash acquired in connection with reverse recapitalization transaction		-			13

The accompanying notes are an integral part of the consolidated financial statements.

F-9

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 1:- GENERAL

Raphael Pharmaceutical Inc (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel. From April 1, 2011 until December 31, 2019, the Company was not active.

On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.

On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021. The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding Common stock into one share of common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share.

On May 14, 2021, Raphael and the Company, completed the Share Exchange pursuant to which 9,459,253 common stock were issued to the shareholders of Raphael so that they became the holders of 90% of the issued and outstanding common stock of the Company immediately after the Share Exchange while the Company’s shareholders hold, following the Share Exchange, 1,051,028 common stock which represents 10% of the Company. On May 19, 2021, as agreed by the parties to the Share Exchange, the Company changed its name to Raphael Pharmaceutical Inc. Following such Share Exchange, Raphael’s activities are the sole activities of the Company.

The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented.

Company’s common stock began public trading on the over the counter market in the U.S. in January 2023 under the symbol “RAPH”.

Going concern and management plans

The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, and raising capital. The Company is still in its development and pre-clinical stage and has not yet generated revenues. The extent of the Company’s future operating losses and the timing of becoming profitable are uncertain. As of December 31, 2022, the Company’s accumulated deficit was $6,026, the net loss for the year then ended was $3,358 and the net cash used in operating activities was $759.

F-10

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 1:- GENERAL (Cont.)

The Company has funded its operations to date primarily through equity financing.

Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.

Management’s plans include, but are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or at all.

Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists in the event that additional funding does not occur. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation:

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).

The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated upon consolidation.

Use of estimate in preparation of financial statements:

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.

F-11

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Financial statements in United States dollars:

The Company’s functional currency is the U.S. dollar (“dollar” or “$”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in currencies other than dollars have been re-measured to dollars. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in currencies other than dollars are reflected in the statements of comprehensive loss as financial expenses, net.

Cash and cash equivalents:

Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less as of the date acquired and that are exposed to insignificant risk of change in value.

Fair value measurements:

The carrying values of Company’s financial assets and liabilities, including cash and cash equivalents, other current assets, related parties, accounts payable and accrued expenses approximate their fair value due to the short-term maturity of these instruments.

Research and development expenses:

Research and development expenses are charged to the statements of comprehensive loss as incurred.

Income taxes:

The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. ASC 740 prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. As of December 31, 2022, and 2021, the Company had a full valuation allowance on its deferred tax assets.

Basic and diluted net loss per share:

Earnings or loss per share (“EPS”) is the amount of earnings attributable to each share of common stock. For convenience, the term is used to refer to either earnings or loss per share. EPS is computed pursuant to ASC 260-10-45. Pursuant to ASC 260-10-45-10 through 260-10-45-16 Basic EPS is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Loss available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock (whether or not paid) from loss from operating loss (if that amount appears in the statements of comprehensive loss) and also from net loss.

F-12

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common stock had been issued during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants.

The net loss per share and the weighted average number of shares used in computing basic and diluted net loss per share is as follows:

	For the Year Ended December 31,
	2022			2021
Numerator:
Net loss applicable to common stockholders	$	(3,358	)	$	(1,625	)

Denominator:
Number of shares of common stock used in computing basic and diluted net loss per share		14,341,518			11,171,704
Net loss of shares of common, basic and diluted	$	(0.23	)	$	(0.15	)

Leases

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires lessees to recognize their leases contracts as assets and liabilities in the financial statements. Furthermore, the ASU requires the Company to continue recognizing expenses but recognize expenses on their statements of comprehensive loss in a manner similar to current lease accounting. The amendments in this ASU are effective January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, to allow a company to elect an optional modified retrospective transition method that applies the new lease requirements through a cumulative-effect adjustment in the period of adoption.

Effective January 2019, the Company adopted the new lease accounting standard. The Company elected to apply the practical expedients permitted under the transition guidance within the new standard. As such, there was no impact on the Company’s financial statements as a result of adopting ASU 2016-02. See note 6a for more details.

Recently issued accounting pronouncements

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). ASU 2016-13 replaces the current incurred loss model guidance with a new method that reflects expected credit losses.

F-13

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES (Cont.)

Under this guidance, an entity would recognize an allowance for credit losses equal to its estimate of expected credit losses on financial assets measured at amortized cost. In November 2019, the FASB extended the effective date of ASU 2016-13 for smaller reporting companies. As a result, ASU 2016-13 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022, with early adoption permitted. The standard did not have a significant impact on the Company’s consolidated financial statements.

In May 2021, the Financial Accountings Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-04, “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815- 40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). The guidance is effective for the Company on January 1, 2022. The standard did not have a significant impact on the Company’s consolidated financial statements.

NOTE 3:- OTHER CURRENT ASSETS

	As of December 31,
	2022		2021

Receivables from governmental authorities	$	38	$	92
Prepaid expenses		5		177

	$	43	$	269

NOTE 4:- OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES

	As of December 31,
	2022		2021

Account payables	$	72	$	107
Accrued expenses		152		165

	$	224	$	272

F-14

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 5:- CONTINGENT LIABILITIES AND COMMITMENTS

Lease commitments:

Starting February 1, 2022, the Company began renting its offices from a third party for a rental monthly fee of approximately $1 per month. The rent period is for a period of one month which renews on a monthly basis.

The Company elected to apply the practical expedients permitted under the transition guidance within the new standard, and the Company also elected not to apply the recognition requirements in the lease standard to short-term leases (less than 12 months) as of the adoption date. As such, there was no impact on the Company’s financial statements as a result of adopting ASU 2016-02.

Rambam research agreement

The Company’s research and development efforts relating to its COVID-19 and rheumatoid arthritis (“RA”) product candidates are being conducted by Rambam Med-Tech Ltd., or Rambam MT, a part of the Rambam Health Care Campus in Israel, in accordance with a Sponsored Research Agreement (the “Research Agreement”), that was entered into by the Company and Rambam MT in July 2019, to be in effect for a period of 48 months and which includes a non-compete extension option for an additional 48 months of research and development. Pursuant to the Research Agreement, the Company agreed to pay Rambam MT $1.4 million in four equal milestone payments, due on the first day of August on each successive year from 2019 through 2022. Furthermore, in accordance with the terms of the Research Agreement, the Company and Rambam MT will have joint ownership of any IP created as a result of research programs covered by such agreement. In addition, subject to commercial sales of any product candidate using the IP created as a part of the research covered by the Research Agreement, the Company is required to pay Rambam MT a royalty in an amount equal to 6% of all net sales, subject to certain deductions, such as taxes paid by any purchaser, transportation and shipping costs, and other customary deductions.

As of December 31, 2022 the Company paid $1.15 million and in the first quarter of 2023 the Company paid the remaining $0.25 million.

In October 2022, the Company and Rambam signed an appendix to the Research Agreement, according to which the objective of the new study will be to identify a novel cannabinoid based patentable formulation to treat Rheumatoid diseases. Total cost of the new study will be $800 + $160 (overhead) + VAT (which consist of $700 + VAT pre-clinical lab research cost, $120 + VAT Mouse model for systemic inflammation and $140 + VAT Mouse model for Rheumatoid Arthritis). The Company’s payments will be according to the payment schedule stipulated in the appendix and will begin in May 2023.

Way of Life Cannabis research agreement

In October 2020, Raphael Israel entered into an engagement agreement with Wolc, pursuant to which, subject to its completing the Share Exchange with Easy Energy, Raphael Israel will be provided with up to 15 liters of CBD oil, from a strain of cannabis during a term of 18 months, to be provided in two to three deliveries of between one to seven liters of CBD oil.

F-15

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 5:- CONTINGENT LIABILITIES AND COMMITMENTS (Cont.)

In accordance with Raphael Israel’s agreement with Wolc, Raphael Israel has agreed to issue to certain persons affiliated with Wolc 3% of Raphael’s issued and outstanding share capital as of the date of the Share Exchange, to be provided in three equal issuances; provided, however, that such persons may elect to receive a cash payment of $100 instead of any one issuance of Raphael’s shares. In addition to the issuance of shares, Raphael Israel has also agreed to pay Wolc a royalty fee equal to 15% of the net royalties generated from sales of Raphael Israel’s pharmaceutical drug products that are developed at Rambam hospital in Israel.

In February 2023 the Company and Wolc signed an appendix to the agreement, refer to Note 11d.

Consulting agreement executive officers:

On July 5, 2022 the Company singed several agreements with it’s executive officers:

●

Service agreement with Chief Executive Officer– the Company entered into an agreement with Sheffa Enterprises Inc, a company wholly owned by the Company’s Chief Executive Officer (“CEO”). According to the terms of the agreement, the CEO will provide services to the Company until December 31, 2024 (“termination date”). The fees for his services will be $20 per month starting January 2023 (until January 2023, the fee will remain to be $10 according to a consultant agreement dated June 2019). In addition, the CEO was granted with 1,000,000 warrants to purchase common stock at an exercise price of $1.12 per share. The warrants exercisable until December 31, 2025. Furthermore, the Company may terminate the agreement prior to the termination date by providing 120 days’ advance written notice and paying the CEO a termination fee equal to the lesser of $360 or the monthly fee agreed, for the remaining term of the agreement.

●

Service agreement with Chief Financial Officer– The services will consist of financial services, legal advice and serve as a director of the Company. Base compensation will be $12 starting January 2023 (between July 2022 and January 2023 the base compensation will be $6). In addition, the CFO was granted with 1,000,000 shares of common stock at no cost and 1,000,000 warrants to purchase common stock at an exercise price of $1 per share. The warrants exercisable until December 31, 2025. The agreement is in place until December 31, 2024 (“termination date”). Furthermore, the Company may terminate the agreement prior to the termination date by providing 120 days’ advance written notice and paying the CFO a termination fee equal to the lesser of $120 or the monthly fee agreed, for the remaining term of the agreement.

●

Consulting agreement with the Chief Technology Officer - the Company entered into an amendment agreement with its Chief Technology Officer (“CTO”). The fees for his services will be $9 per month with the last payment being due and payable on December 31, 2022. According to the terms of the agreement, the CTO will provide consulting services to the Company until December 31, 2023 (“termination date”). In addition, the CTO was granted with 990,000 warrants to purchase common stock at an exercise price of $0.01 per share. The warrants exercisable until July 5, 2024.

F-16

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 5:- CONTINGENT LIABILITIES AND COMMITMENTS (Cont.)

Furthermore, the CTO will receive 15% of the Company’s net royalties’ from worldwide sales of any of the Company’s cannabis-based medical indications treating COVID-19, and will receive 15% of the net royalty’s income the Company will get for its medical cannabis indication molecules based, for treating Rheumatoid Arthritis (RA) once the Company starts generating revenues. The CTO will be granted with additional 350,000 warrants to purchase common stock at an exercise price of $0.01 per share if the Company will apply for any clinical trial of cannabis based treatment, or will begin any other new cannabis related research. Furthermore, the Company may terminate the agreement prior to the termination date by providing 120 days’ advance written notice and paying the CTO a termination fee equal to the fees that were paid or payables to him for three years pursuant to this agreement.

NOTE 6:- STOCKHOLDERS’ EQUITY

Between January and September 2021, the Company raised $578 (net of issuance expenses of $52) and issued 1,632,509 shares of common stock. An amount of $160 was received before the Share Exchange (see Note 1a) and an amount of $470 was received after the Share Exchange.

On May 14, 2021, the Company, completed a Share Exchange pursuant to which the Company issued 9,459,253 common stock to the shareholders of Raphael, and the shareholders of Raphael became the holders of 90% of the issued and outstanding common stock of the Company while the Company’s shareholders hold, immediately following the Share Exchange, 1,051,028 common stock, which represents 10% of the Company (see also Note 1a).

In October through December 2021, the Company raised $820 and issued 715,250 shares of common stock and 441,000 warrants to purchase common stock in private placement. The warrants are exercisable at an exercise price of $1.12-$1.25 per share into common stock and expire in November and December 2022. As part of the fund raising, the Company issued 112,500 common stock to certain third parties as a finder fee. As such, an amount of $102 was recorded as non cash issuance costs.

On March 2, 2022, the Company raised $10 and issued 50,000 shares of common stock and 30,000 warrants to purchase common stock at an exercise price of $1.25 per share to certain investors of the Company. The warrants were classified as equity and are exercisable until February 28, 2023.

On March 15, 2022, the Company issued 270,000 shares of common stock and 180,000 warrants to purchase common stock at an exercise price of $1.13 per share to Company’s service provider in consideration of past services at the amount of $150. The warrants were classified as equity and are exercisable until December 31, 2023.

On April 28, 2022, the Company signed an agreement to raise $50 and to issue 300,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $0.7 per share to certain investor of the Company. The warrants are exercisable until April 30, 2024.

F-17

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 6:- STOCKHOLDERS’ EQUITY (Cont.)

On April 28, 2022 the Company and a certain investor signed a finder fee agreement according to which the Company will issue to the investor 70,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $0.5 per share. The warrants will be exercisable until April 30, 2024. The agreement will become effective once the investor will provide the Company with an equity investment of $550. The shares were issued following May 2022 investment. The value of the shares issued was based on the value of the service provided and amounted to $70 which was recorded as issuance cost.

On May 2, 2022, the Company signed several agreements to raise $250 and to issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share to certain investors of the Company. The warrants are exercisable until April 30, 2024.

In addition, it was agreed that the Company will issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share to a certain investor in consideration of additional $250 if the Company’s stock will be publicly traded on the OTC market prior to August 15, 2022. The additional warrants once issued will be exercisable for 2 years. In January 2023 the investor exercised his option for additional investment, refer to Note 11c.

On June 27, 2022, the Company signed an agreement to raise $50 and to issue 35,000 shares of common stock to certain investor of the Company.

On June 30, 2022, the Company issued 280,000 shares of common stock and 105,000 warrants to purchase common stock at an exercise price of $1.12 per share to Company’s former director for his services. The warrants will be exercisable until June 30, 2024. The value of the shares and warrants issued was based on the value of the service provided and amounted to $290.

On July 27, 2022, the Company issued 1,000,000 shares of common stock and 1,000,000 warrants to Company’s CFO, refer to Note 6d. In addition, the Company issued 2,201,000 warrants to Company’s executive officers and directors pursuant a consultant agreement, refer to Note 6d. The value of the shares and warrants issued was based on the value of the service provided and amounted to $1,800.

On July 27, 2022, the Company issued 100,500 shares of common stock to Wolc in connection with the services agreement dated October 2020. The value of the shares issued was based on the value of the service provided and amounted to $100.

On September 8, 2022, the Company issued 56,000 shares of common stock to certain investor of the Company pursuant to a share purchase agreement for total consideration of $63.

On September 8, 2022, the Company issued 102,000 shares of common stock to certain service provider of the Company pursuant to consultant agreement. The value of the shares issued was based on the value of the service provided and amounted to $100.

On October 21, 2022, the Company signed an agreement to raise $50 and to issue 50,000 shares of common stock and 50,000 warrants to purchase common stock at an exercise price of $1.4 per share to certain investor of the Company. The warrants are exercisable until September 30, 2024. The shares of common stock were issued on October 26, 2022.

F-18

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 6:- STOCKHOLDERS’ EQUITY (Cont.)

On October 26, 2022, the Company issued 90,000 shares of common stock to certain investor of the Company pursuant to an exercise of 90,000 warrants for total consideration of approximately $100.

On November 4, 2022, the Company signed an agreement to raise $100 and to issue 80,000 shares of common stock and 20,000 warrants to purchase common stock at an exercise price of $1.5 per share to certain investor of the Company. The warrants are exercisable until September 30, 2023. The shares of common stock were issued on January 10, 2023.

In December 2022, the Company signed an agreement to raise $20 and to issue 15,750 shares of common stock and 47,250 warrants to purchase common stock at an exercise price of $1.25 per share to certain investor of the Company. The warrants are exercisable until December 31, 2024. The shares of common stock were issued on January 10, 2023.

In December 2022, the Company signed an agreement to raise $200 and to issue 160,000 shares of common stock and 40,000 warrants to purchase common stock at an exercise price of $1.5 per share to certain investor of the Company. The warrants are exercisable until December 31, 2023. The shares of common stock were issued on January 10, 2023.

As of December 31, 2022, there were 4,461,250 warrants outstanding.

NOTE 7:- RELATED PARTIES BALANCES AND TRANSACTIONS

Balances

The following related party payables are included in accounts payable and accrued expenses.

	As of December 31,
	2022		2021
Payables to related party - Officers (*)		3		22
		3		22

(*)	Relates to Chief Executive Officer’s and Chief Financial Officer’s services

F-19

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 7:- RELATED PARTIES BALANCES AND TRANSACTIONS (Cont.)

Transactions

	Year ended December 31,
	2022		2021
Consulting services (*)		113		120
Legal fee (**)		72		75
		185		195

(*)	Including salary expenses to Company’s CEO. For further details on the consulting agreement with Company’s CEO, refer to Note 6d.

(**)	Including legal services provided to Company’s subsidiary by Company’s Chief Financial Officer with respect to an agreement between the Company and its Chief Financial Officer.

(***)

During 2022, Company’s Chief Technology Officer fees and Directors’ fee were $105 and $17, respectively.

(****)

In 2022, the Company recorded share-based compensation expenses of $2,090, which includes $250 to Company’s CEO, $1,000 to Company’s Chief Financial Officer, $500 to Company’s Chief Technology Officer and Director, $50 to Company’s current director and $290 to Company’s former director, refer to Notes 6d and 7k.

NOTE 8:- TAXES ON INCOME

Income tax rates applicable to the Company in 2021 and 2020 was 21%.

Foreign income tax:

Income tax rates:

Presented hereunder are the income tax rates relevant to the Company’s Israeli subsidiary

2021 - 23%

2020 - 23%

F-20

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 8:- TAXES ON INCOME (Cont.)

As of December 31, 2022, the Company had U.S. federal net operating loss carryforwards of approximately $XX available to reduce future taxable income. There is a limitation on the amount of taxable income that can be offset by carryforwards after a change in control (generally greater than a 50% change in ownership). Losses from 2018 and forward that can only offset 80% of taxable income in a future year.

The Company’s Israeli subsidiary have estimated total available carryforward operating tax losses for Israeli income tax purposes of approximately $XX as of December 31, 2022.

Deferred income taxes:

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:

	As of December 31,
	2022		2021
Deferred tax assets:
Net operating loss carry forward	$		$	5,746

Deferred tax asset before valuation allowance				1,243
Valuation allowance				(1,243	)

Net deferred tax asset	$	-	$	-

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance as of December 31, 2022 and 2021.

Reconciliation of the theoretical tax expense to the actual tax expense:

The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.

F-21

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 8:- TAXES ON INCOME (Cont.)

	Year ended December 31,
	2022			2021

Net loss, as reported in the consolidated statements of comprehensive loss	$	3,358		$	1,625
Statutory tax rate		21	%		21	%
Computed “expected” tax income		705			341
Valuation allowance		(705	)		(341	)

Taxes on income	$	-		$	-

NOTE 9:- SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA

Research and development expenses:

	For the Year Ended December 31
	2022		2021

Subcontractors and consultants	$	551	$	765
Share based compensation		600		-
Laboratory services		27		11

	$	1,178	$	776

General and administrative expenses:

	For the Year Ended December 31
	2022		2021

Professional services	$	289	$	697
Share based compensation		1,690		-
Consulting services		113		120
Rent and office maintenance		9		31
Others		38		5

	$	2,139	$	853

F-22

RAPHAEL PHARMACEUTICAL INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S dollars in thousands (except for share and per share data)

NOTE 9:- SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA (Cont.)

Financial expenses, net:

	For the Year Ended December 31
	2022		2021

Bank fees	$	3	$	2
Exchange rate differences		38		(6	)
Total financial expenses, net	$	41	$	(4	)

NOTE 10:- SUBSEQUENT EVENTS

In January 2023, the Company issued 255,750 shares of common stock following certain share purchase agreements dated November and December 2022.

On December 30, 2022, the Company signed an agreement to raise $7.5 and to issue 6,000 shares of common stock and 18,000 warrants to purchase common stock at an exercise price of $1.25 per share to certain investor of the Company. The warrants are exercisable until February 28, 2024. The investment above and share issuance took place in January 2023.

On January 8, 2023, certain investor of the Company and the Company signed an agreement to raise $250 and to issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share following the exercise of an option for additional investment (refer to Note 7h). The warrants are exercisable until April 30, 2024.

In February 2023, the Company and Wolc signed an appendix to the research agreement, according to which the parties agreed that Wolc provided to the Company 12 out of 15 liters of CBD oil, from a strain of cannabis and the Company will transfer to Wolc the remaining stock per research agreement. In addition, Wolc will transfer the remaining 3 liters of CBD oil to the Company upon Company’s request.

F-23

(b) Exhibits.

Exhibit Number		Description

3.1		Restated Certificate of Incorporation (incorporated by reference from Amendment No. 2 to our registration statement on Form 10 filed September 23, 2021).

3.2		Bylaws (incorporated by reference from Amendment No. 2 to our registration statement on Form 10 filed September 23, 2021).

4.1		Description of Securities (incorporated by reference from our Annual Report on Form 10-K filed March 30, 2022).

10.1		Share Exchange Agreement by and between Easy Energy, Inc. and Raphael Pharmaceutical Ltd. (incorporated by reference from Amendment No. 2 to our registration statement on Form 10 filed September 23, 2021).

10.2		Contractual Agreement between Raphael Pharmaceutical Ltd. and Way of Life Cannabis Ltd. (incorporated by reference from Amendment No. 2 to our registration statement on Form 10 filed September 23, 2021).

10.3		Sponsored Research Agreement with Rambam Med-Tech Ltd. (incorporated by reference from Amendment No. 2 to our registration statement on Form 10 filed September 23, 2021).

21.1		List of Subsidiaries of the Company (incorporated by reference from Amendment No. 2 to our registration statement on Form 10 filed September 23, 2021).

31.1*		Certification of Chief Executive Officer pursuant to Sec. 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Chief Financial Officer pursuant to Sec. 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

32.2**		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

101*		The following materials from the Company’s Annual Report on Form 10-K for the period ended December 31, 2021 formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Comprehnesive Loss, (iii) the Statements of Changes in Stockholders’ Equity (Deficit), (iv) the Consolidated Statements of Cash Flows and (v) related notes to these financial statements, tagged as blocks of text and in detail.**

104*		Cover Page Interactive Data File

*	Filed herewith.
**	Furnished herewith.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RAPHAEL PHARMACEUTICAL INC.

Date: May 25, 2023	By:	/s/ Shlomo Pilo
		Shlomo Pilo Chief Executive Officer (Principal Executive Officer)

	By:	/s/ Guy Ofir
		Guy Ofir
		Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Date: May 25, 2023	By:	/s/ Shlomo Pilo
		Shlomo Pilo
		Chief Executive Officer (Principal Executive Officer)

Date: May 25, 2023	By:	/s/ Guy Ofir
		Guy Ofir
		Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

Date: May 25, 2023	By:	/s/ Yehuda Eliya
		Yehuda Eliya
		Director

Date: May 25, 2023	By:	/s/ Igal Louria Hayon
		Igal Louria Hayon
		Chief Technology Officer and Director

EX-31.1 2 f10k2022a1ex31-1_raphael.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Shlomo Pilo, certify that:

1. I have reviewed this Annual Report on Form 10-K/A of Raphael Pharmaceutical Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 25, 2023	By:	/s/ Shomo Pilo
		Shlomo Pilo
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 f10k2022a1ex31-2_raphael.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a) AND 15d-14(a)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Guy Ofir, certify that:

1. I have reviewed this Annual Report on Form 10-K/A of Raphael Pharmaceutical Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 25, 2023	By:	/s/ Guy Ofir
		Guy Ofir
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 f10k2022a1ex32-1_raphael.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the annual report of Raphael Pharmaceutical Inc., or the Company, on Form 10-K/A for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Shlomo Pilo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 25, 2023	/s/ Shlomo Pilo
	Shlomo Pilo
	Chief Executive Officer
	(Principal Executive Officer)

EX-32.2 5 f10k2022a1ex32-2_raphael.htm CERTIFICATION

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the annual report of Raphael Pharmaceutical Inc., or the Company, on Form 10-K/A for the period ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Guy Ofir, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: May 25, 2023	/s/ Guy Ofir
	Guy Ofir
	Chief Financial Officer
	(Principal Financial Officer)

GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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image_002.jpg GRAPHIC begin 644 image_002.jpg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end GRAPHIC 8 image_003.jpg GRAPHIC begin 644 image_003.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#TO7?B;X8\ M-ZQ+I>I7,Z742JS*D#, &&1R.O&*S_\ A=G@G_G]NO\ P$?_ KR'XS?\E.U M'_KC#_Z *Y/1]!U3Q#>26FD64EW/&AD9(R 0N0,G) ZF@=CZ3M/B]X)NY @U MCR"3_P O$+H/S(P*[&RO;6_MDN+.ZBN8'^[+$X93^(XKX_UCPQKOA]4.K:5= M6<;G"NZ_*3Z;AD9J7POXKU;PAJBWNF3E5R#-;L' M=;M/$>@VFKV9_-PP/X@T )>745E93W7_ &WIN_\ N_:TS^6:TXW21 \;JR-R&4Y!_&@"MJ>HV^D: M5=:C=EA;VT;2R%5R0H&3Q7"_\+N\%]?M-Y['[(U=CXDTX:OX;U'3CZZ9J%OJNE6NH6;$ MVUS$LL1(P2I&1Q3;[5=.T]2;V_M;< <^=*J_SJGH=O;Z#X8TRQDO(GCMK=(1 M.2%63"@9'UKY)UW;)XCU1^'S>S$,<'(WGI0!]?Z5K.FZY ]QI=[!=PI(8VDA M;VMKX(NUGN88F-^YVR2!J->VJ1)*US"LM 'JE M%1I(DJ*\;!D89#+R"*;/<0VT1EGE2*,=6=@H'XF@":BLA?$N@R2>6FMZ<7S] MT729_+-:B,&4,I!4\@@\4 /HHHH **** /EWXS?\E/U'_KC#_P"@"M?X!_\ M([ZA_P!@]O\ T8E9'QF_Y*?J/_7&'_T 5K_ /_D=]0_[![?^C$H'T/>]8TNU MUG2;K3KV)9+>XC,;JPSP>_X=?PKXUN;=K2]GMG8L\,K1DGN5)!S[\"OM6:1( M(7ED8*B*69CV Y)KXNU"X6\U2\N5^[/<22KCT9B1^>K64C M_N[:Z#K[!UY_52?QKS_XA_$;4/%6JSVEE"/$'B"RDO-)T M>2XMHR1Y@**&([+N(W'Z56TK5]8\)ZKYVGW$]C=P/MDCY R#RKIWZ=#FNET7 MXM>)= T>VTJQ-@MK;($0/;Y;'O\ ,.>_XURVMZS<^(-9N-5O?)6YN"&D\E=J MD@!+OA9>:M&BQR/83I-%VCD"$,/IW'J"*^5E_U8^@_E7M MOPDE9OA;XNB+95/.*C/3,%>)+_JQ]!_*@#ZG\%:G:Z-\']+U*\V0.IP1EC^'2O2?$%Q)!^S=I* MQL5$P@1L?W=Y;^8KQ:*,2SQQ'@/(J<]@3C- %Y?#>L-I7]K#1[MM.QN-SY!\ MO X_+WK2\)>-M8\'WT+3EL5B'V9(A M"(SW0#&/RXKXRO(4MKZY@3!2*9XU/LK$#_/M3 ^I?$VIVFM_"G5=4LW\RUNM M+EDC)'."AX(]1^F#7RCY2$?<7\J]S\$W$DW[/>OQN21 EW&N?3:&_FQKP^D! M[?XULKB_^!?A>&TLYKF0"U?RX8BY \IAG Z"O$2C(Y1EVLI*LI&"I]#D5]>> M _\ D0/#_P#V#X?_ $ 5\HZY_P C'JG_ %^S_P#HPT 0V^D7^H1&6UTR[ND! MV[X;9I!GTR!_6O4?&.CZA/\ !OP=;1Z;>/-$Q\R%8&9XQL;[P R/QKL?@'_R M(UY_V$'_ /0$KU0TQ'Q 5*D@@AAP01@C''([59@T;4+Z'SK72KNYBS@20VSR MKGTSM-,O/^0A=?\ 7:3_ -"-?1WP,_Y)RO\ U^3?S%!3-&UUV+PA\)=-U*]B M=6M=.A7R"-K-)M4!,'ID]?2OG'Q#XFU;Q3?->:O=O.2"6UPUI=07*!"T$BR*'&1E2",_E2$;=U MX"\36>B_VO<:%<)8[=[.0I(7^\4SD#ZBM#P+\0-2\(:G C7,DVCNV)[9F+*J MD_?3^Z1U].*TY_C7XMN;>2"4Z;Y4BE& MB.".WS&O.L*(]@.,#'Z4P/MN%TE MC62-@R,-RL.C ]#4U8/@N5I_ ^@RL6)=FW+!LY(.>E>G^/?A+K?BOQ?=: MQ9WVGQ03)&JI,7W?*N#G"FN<_P"%!>)?^@II7YR?_$T@,_Q=\8M7\2:?+IMG M:)IEI."LQ63?*RGJ-W ^E>?6=G<:A>P65G \UQ.^R.)!RQ/0#_&O6[+]G_4 MVE'V_7;6*+H1;PEV_P#'L5Z?X1^'NA>#OWMA"TMVZ[7NISND/L.@4>P%,9#X M?\%1:3\.&\,NRM+/:R)<2#HTD@.XCU )P/I7RS^@38UQ-9"03@=&+!2=WKGO\ 6M[4O&WPEL(R8=(L;YL?=M], M7^;**XVY^!GBZ&8K#+IEPG]Y9F7/X%>*L6/P&\27+XO[[3[2+/.QFE;'L, 9 M_&@#V34-/TNP\%ZPVD65K:P3V,LN+>)4#YB.#@8[8KY&CX1?H*^PAHDT/@LZ M$MSYTBV)M%GD&W<=FT$@9KQ1?@#XD"@?VII7 QUD_P#B: .N_L*7Q!^SQ8VE MNA>YBLTGB0?Q,C;MOX@$?C7SV,X!4E3V/H?\:^P?".CS^'O"6FZ3F:X/QG\%[/7;Z74=#N$T^ZE;=+"ZDPNW=ACE3].#0 0?''01X;6> M5;@ZL(0&M?*.&EQ_>Z8)YKY\=VD9I93N9R7<^I/4CVKT<_ [QB)-N=-*YQYG MVD_G@K7;>$/@C;:5?1:AK]Y'?31$-';PH5B!'0L3RWKT'(% $NB:'/H?[/\ MJ,=RK)/J[U.!_P!\A:^?*^QO$NF2:SX9U+3+=T26ZMGA1GSM!88& M<=J\._X4'XEVX_M72L].LG_Q/2@#VCP)_P D_P##_P#V#X?_ $ 5\J>(X9+; MQ3J\,JE9$OIP1GI\YQ7UKX;TZ;1_#6FZ9.R/+:6R0NR9VDJH&1GM7G'C_P"$ M+^)-6EUG1KJ&WNYP//@G7Y)&'&X,,X)&.* .3^%WQ)T;PAH5YINK17.6N3/% M)!'OW @+@\C!&W]:]H\'^*[;QCHAU2TMYX(/.>)5FQN.WOP37AL/P-\822A9 M&TV)>[-<%OT"U[/X!\*2^#?"ZZ3/=)=2>:\K.B;0-W;!- 'ROJ,;PZI>QNO[ MQ+B12ON&.?UKU/X:?$[0_"GA9]*U2*\\U;AY4>&/<'#8]Q@BM[Q[\')M=UJX MUC0KJ"&6X.^>VN,JI?NRL!QGJ0>^3WKD+?X&^+Y90LKZ; G]]IRV/H M '6^ M/KI?B'\)H_$6G6<\8L[IIA%)@OY:EDGXU]8>"O"Q\*>$H=%FN$O"I=G?R]JMO))&#GCFO/O%'P*M[R[> MZ\.WJ6?F,2UI.I:-2>3L89*_2D!;T[QA\)KVT6:XT[3+*8C+P3Z:-RGOT0@\ M^E3:7XB^&6M^(K71--T*RGEN-VR8Z>B1@@%L?, >W85P#? _QDK;0--(SU^T MG^JUTWA'X*ZMI.NV.K:CJUM&;299EBME:1F(Z@L0,?D: /2];U-= L[:TT^W MBC.W;$H7"1JN. !^'%9FD>*;QK^.&\998I6"[MH4J3["MGQ#H9U6.-X75)X\ MA=W0CTK*TGPIJ= ZBBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 6**** "BBB@ HHHH **** "BBB@#_V0$! end EX-101.SCH 9 cik0000141539-20221231.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statements of Changes Stockholders’ in Equity (Deficit) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - General link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Other Current Assets link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Other Accounts Payable and Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Contingent Liabilities and Commitments link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Stockolders’ Equity link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Related Parties Balances and Transactions link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Taxes on Income link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Selected Statements of Comprehensive Loss Data link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Other Current Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Other Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Related Parties Balances and Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Taxes on Income (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Selected Statements of Comprehensive Loss Data (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - General (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Other Current Assets (Details) - Schedule of other current assets link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Other Accounts Payable and Accrued Expenses (Details) - Schedule of other accounts payable and accrued expenses link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Contingent Liabilities and Commitments (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Stockolders’ Equity (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Related Parties Balances and Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Related Parties Balances and Transactions (Details) - Schedule of related party balances link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Related Parties Balances and Transactions (Details) - Schedule of related party transactions link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Taxes on Income (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Taxes on Income (Details) - Schedule of income tax rate link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Taxes on Income (Details) - Schedule of deferred income taxes link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Taxes on Income (Details) - Schedule of reconciling item between the statutory tax rate of the Company and the effective tax rate link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Selected Statements of Comprehensive Loss Data (Details) - Schedule of research and development expenses link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Selected Statements of Comprehensive Loss Data (Details) - Schedule of general and administrative expenses link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Selected Statements of Comprehensive Loss Data (Details) - Schedule of financial expenses, net link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 cik0000141539-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 11 cik0000141539-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 12 cik0000141539-20221231_lab.xml XBRL LABEL FILE Total current assets Total assets Total current liabilities Total stockholders’ equity Balance Balance Total liabilities and stockholders’ equity Operating loss Net loss and comprehensive loss Net loss Net loss (in Dollars) Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Net cash used in operating activities (in Dollars) Net cash provided by investing activities Net cash provided by financing activities Change in cash and cash equivalents Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the year General [Abstract] Schedule of net loss per share and the weighted average number of shares [Abstract] Other Current Assets [Abstract] Schedule of Other Current Assets [Abstract] Total Other current assets Schedule of Other Accounts Payable and Accrued Expenses [Abstract] Total accounts payable and accrued expenses Contingent Liabilities and Commitments [Abstract] Shareholders Schedule of Related Party Balances [Abstract] Schedule of Related Party Transactions [Abstract] Geographical [Axis] Schedule of Deferred Income Taxes [Abstract] Schedule of Reconciling the Statutory Tax Rate of the Company and the Effective Tax Rate [Abstract] Schedule of Research and Development Expenses [Abstract] Schedule of General and Administrative Expenses [Abstract] Schedule of Financial Expenses Net [Abstract] Document Type Document Annual Report Current Fiscal Year End Date Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(g) Security Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company ICFR Auditor Attestation Flag Entity Shell Company Entity Common Stock, Shares Outstanding Amendment Description Auditor Firm ID Auditor Name Auditor Location Amendment Flag Document Fiscal Period Focus Entity Central Index Key Entity Public Float Assets Current assets: Cash and cash equivalents Non-Current assets: Fixed asset, net Liabilities and stockholders’ equity (deficit) Current liabilities: Other accounts payable and accrued expenses Payable to related party Stockholders’ equity (deficit): Common stock, $0.01 par value: Authorized: 21,020,560 shares; Common stock, $0.01 par value:Authorized: 21,020,560 shares;Issued and outstanding: 15,624,040 and 12,970,540 as of December 31, 2022 and December 31, 2021, respectively Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock share issued Common stock, shares outstanding Additional paid-in capital Accumulated deficit Research and development expenses General and administrative expenses Basic and diluted net loss per share (in Dollars per share) Net loss of shares of common, basic and diluted Basic and diluted net loss per share (in Dollars per share) Net loss of shares of common, basic and diluted Weighted average number of common shares used in computing basic and diluted net loss per share (in Shares) Weighted average number of common shares used in computing basic and diluted net loss per share (in Shares) Number of shares of common stock used in computing basic and diluted net loss per share Issuance of common stock and warrants Issuance of common stock and warrants (in Shares) Issuance of common stock in exchange for services Issuance of common stock in exchange for services (in Shares) Effect of reverse recapitalization transaction (Notes 1a and 7b) Effect of reverse recapitalization transaction (Notes 1a and 7b) (in Shares) Cash flows from operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Share-based payment in exchange for services Changes in: Related parties Other accounts payables and accrued expenses Cash flows from investing activities Cash flows from financing activities Receipt of a loan Proceeds from issuance of common stock and warrants Cash acquired in the reverse recapitalization Non cash supplement Issuance of shares for past services (Note 7e) Non cash issuance costs (Note 7g) (*) Cash acquired in the reverse recapitalization: Current assets (excluding cash and cash equivalents) Current liabilities Reverse recapitalization effect on equity Cash acquired in connection with reverse recapitalization transaction Total financial expense, net Other current assets Purchase of fixed assets Common stock Common Stock [Member] Common stock [Member] Additional paid-in capital Accumulated deficit GENERAL SIGNIFICANT ACCOUNTING POLICIES Schedule of net loss per share and the weighted average number of shares Numerator: Net loss applicable to common stockholders Denominator: OTHER CURRENT ASSETS Schedule of other current assets Receivables from governmental authorities Prepaid expenses OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES Schedule of other accounts payable and accrued expenses Account payables Accrued expenses CONTINGENT LIABILITIES AND COMMITMENTS STOCKOLDERS’ EQUITY RELATED PARTIES BALANCES AND TRANSACTIONS Schedule of related party balances Payables to related party - Officers Total Payables to related party Schedule of related party transactions EX-101.PRE 13 cik0000141539-20221231_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2022	Mar. 25, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	Raphael Pharmaceutical Inc.
Document Type	10-K/A
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		16,135,790
Entity Public Float			$ 0
Amendment Flag	true
Amendment Description	Raphael Pharmaceutics Inc. (the “Company”) is filing this Amendment No. 1 (the “Amendment”) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 24, 2023 (the “Original Filing”), for the sole purpose of amending and restating the disclosure provided in Item 9 of Part II and including the audit letter of Brightman Almagor Zohar & Co., a firm in the Deloitte global network (the “Former Auditor”), in Item 15 of Part IV, which were inadvertently omitted from the Original Filing.In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the certifications pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 have been re-executed as of the date of, and are re-filed as part of, this Amendment as Exhibits 12.1, 12.2, 13.1 and 13.2.Other than expressly set forth herein, this Amendment does not reflect events occurring after the date of the filing of the Original Filing or modify or update any of the other disclosures contained therein in any way.
Entity Central Index Key	0001415397
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-53002
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	26-0204284
Entity Address, Address Line One	4 Lui Paster
Entity Address, City or Town	Tel Aviv-Jaffa
Entity Address, Country	IL
Entity Address, Postal Zip Code	6803605
City Area Code	(972)
Local Phone Number	52-775-5072
Title of 12(g) Security	Common Stock, $0.01 par value
Entity Interactive Data Current	Yes
Auditor Firm ID	6629
Auditor Name	Brightman Almagor Zohar & Co
Auditor Location	Tel Aviv, Israel

XML 15 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 288	$ 153
Other current assets	43	269
Total current assets	331	422
Non-Current assets:
Fixed asset, net	2
Total assets	333	422
Current liabilities:
Other accounts payable and accrued expenses	224	272
Payable to related party	3	22
Total current liabilities	227	294
Stockholders’ equity (deficit):
Common stock, $0.01 par value:Authorized: 21,020,560 shares;Issued and outstanding: 15,624,040 and 12,970,540 as of December 31, 2022 and December 31, 2021, respectively	157	130
Additional paid-in capital	5,975	2,665
Accumulated deficit	(6,026)	(2,667)
Total stockholders’ equity	106	128
Total liabilities and stockholders’ equity	$ 333	$ 422

XML 16 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	21,020,560	21,020,560
Common stock, shares issued	15,624,040	12,970,540
Common stock, shares outstanding	15,624,040	12,970,540

XML 17 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Research and development expenses	$ 1,178	$ 776
General and administrative expenses	2,139	853
Operating loss	3,317	1,629
Total financial expense, net	41	(4)
Net loss and comprehensive loss	$ 3,358	$ 1,625
Basic and diluted net loss per share (in Dollars per share)	$ 0.23	$ 0.15
Weighted average number of common shares used in computing basic and diluted net loss per share (in Shares)	14,341,518	11,171,704

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

XML 18 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Basic and diluted net loss per share (in Dollars per share)	$ 0.23	$ 0.15
Weighted average number of common shares used in computing basic and diluted net loss per share (in Shares)	14,341,518	11,171,704

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

XML 19 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes Stockholders’ in Equity (Deficit) - USD ($)
$ in Thousands

Common stock

Additional paid-in capital

Accumulated deficit

Total

Balance at Dec. 31, 2020

^[1]

$ 95

$ 905

$ (1,043)

$ (43)

Balance (in Shares) at Dec. 31, 2020

^[1]

9,459,253

Issuance of common stock and warrants

$ 25

1,265

1,290

Issuance of common stock and warrants (in Shares)

2,460,259

Effect of reverse recapitalization transaction (Notes 1a and 7b)

$ 10

496

506

Effect of reverse recapitalization transaction (Notes 1a and 7b) (in Shares)

1,051,028

Net loss

(1,625)

Balance at Dec. 31, 2021

$ 130

2,666

(2,668)

128

Balance (in Shares) at Dec. 31, 2021

12,970,540

Issuance of common stock and warrants

$ 8

885

893

Issuance of common stock and warrants (in Shares)

831,000

Issuance of common stock in exchange for services

$ 19

2,424

2,443

Issuance of common stock in exchange for services (in Shares)

1,822,500

Net loss

(3,358)

Balance at Dec. 31, 2022

$ 157

$ 5,975

$ (6,026)

$ 106

Balance (in Shares) at Dec. 31, 2022

15,624,040

[1]	Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the reverse recapitalization transaction and to reflect adjustment to the share par value (refer to Note 1a).

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 20 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (3,358)	$ (1,625)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based payment in exchange for services	2,290
Changes in:
Other current assets	226	(41)
Related parties	(19)	13
Other accounts payables and accrued expenses	102	234
Net cash used in operating activities	(759)	(1,419)
Cash flows from investing activities
Purchase of fixed assets	(2)
Net cash provided by investing activities	(2)
Cash flows from financing activities
Receipt of a loan		174
Proceeds from issuance of common stock and warrants	896	1,290
Cash acquired in the reverse recapitalization		13
Net cash provided by financing activities	896	1,477
Change in cash and cash equivalents	135	58
Cash and cash equivalents at the beginning of the year	153	95
Cash and cash equivalents at the end of the year	288	153
Non cash supplement
Issuance of shares for past services (Note 7e)	150
Non cash issuance costs (Note 7g)	70	102
*() Cash acquired in the reverse recapitalization:**
Current assets (excluding cash and cash equivalents)		(531)
Current liabilities		38
Reverse recapitalization effect on equity		506
Cash acquired in connection with reverse recapitalization transaction		$ 13

XML 21 R8.htm IDEA: XBRL DOCUMENT

General

12 Months Ended

Dec. 31, 2022

General [Abstract]

GENERAL

NOTE 1:- GENERAL

Company’s common stock began public trading on the over the counter market in the U.S. in January 2023 under the symbol “RAPH”.

Going concern and management plans

The Company has funded its operations to date primarily through equity financing.

XML 22 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

General [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation:

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).

The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated upon consolidation.

Use of estimate in preparation of financial statements:

Financial statements in United States dollars:

Cash and cash equivalents:

Fair value measurements:

Research and development expenses:

Research and development expenses are charged to the statements of comprehensive loss as incurred.

Income taxes:

Basic and diluted net loss per share:

The net loss per share and the weighted average number of shares used in computing basic and diluted net loss per share is as follows:

	For the Year Ended December 31,
	2022			2021
Numerator:
Net loss applicable to common stockholders	$	(3,358	)	$	(1,625	)

Denominator:
Number of shares of common stock used in computing basic and diluted net loss per share		14,341,518			11,171,704
Net loss of shares of common, basic and diluted	$	(0.23	)	$	(0.15	)

Leases

Recently issued accounting pronouncements

XML 23 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets

12 Months Ended

Dec. 31, 2022

Other Current Assets [Abstract]

OTHER CURRENT ASSETS

NOTE 3:- OTHER CURRENT ASSETS

	As of December 31,
	2022		2021

Receivables from governmental authorities	$	38	$	92
Prepaid expenses		5		177

	$	43	$	269

XML 24 R11.htm IDEA: XBRL DOCUMENT

Other Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2022

Payables and Accruals [Abstract]

OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 4:- OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES

	As of December 31,
	2022		2021

Account payables	$	72	$	107
Accrued expenses		152		165

	$	224	$	272

XML 25 R12.htm IDEA: XBRL DOCUMENT

Contingent Liabilities and Commitments

12 Months Ended

Dec. 31, 2022

Contingent Liabilities and Commitments [Abstract]

CONTINGENT LIABILITIES AND COMMITMENTS

NOTE 5:- CONTINGENT LIABILITIES AND COMMITMENTS

Lease commitments:

Rambam research agreement

As of December 31, 2022 the Company paid $1.15 million and in the first quarter of 2023 the Company paid the remaining $0.25 million.

Way of Life Cannabis research agreement

In February 2023 the Company and Wolc signed an appendix to the agreement, refer to Note 11d.

Consulting agreement executive officers:

On July 5, 2022 the Company singed several agreements with it’s executive officers:

●

XML 26 R13.htm IDEA: XBRL DOCUMENT

Stockolders’ Equity

12 Months Ended

Dec. 31, 2022

Stockolders’ Equity [Abstract]

STOCKOLDERS’ EQUITY

NOTE 6:- STOCKHOLDERS’ EQUITY

On June 27, 2022, the Company signed an agreement to raise $50 and to issue 35,000 shares of common stock to certain investor of the Company.

On September 8, 2022, the Company issued 56,000 shares of common stock to certain investor of the Company pursuant to a share purchase agreement for total consideration of $63.

On October 26, 2022, the Company issued 90,000 shares of common stock to certain investor of the Company pursuant to an exercise of 90,000 warrants for total consideration of approximately $100.

As of December 31, 2022, there were 4,461,250 warrants outstanding.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 27 R14.htm IDEA: XBRL DOCUMENT

Related Parties Balances and Transactions

12 Months Ended

Dec. 31, 2022

NOTE 7:- RELATED PARTIES BALANCES AND TRANSACTIONS

Balances

The following related party payables are included in accounts payable and accrued expenses.

	As of December 31,
	2022		2021
Payables to related party - Officers (*)		3		22
		3		22

(*)	Relates to Chief Executive Officer’s and Chief Financial Officer’s services

Transactions

	Year ended December 31,
	2022		2021
Consulting services (*)		113		120
Legal fee (**)		72		75
		185		195

(*)	Including salary expenses to Company’s CEO. For further details on the consulting agreement with Company’s CEO, refer to Note 6d.

(**)	Including legal services provided to Company’s subsidiary by Company’s Chief Financial Officer with respect to an agreement between the Company and its Chief Financial Officer.

(***)

During 2022, Company’s Chief Technology Officer fees and Directors’ fee were $105 and $17, respectively.

(****)

XML 28 R15.htm IDEA: XBRL DOCUMENT

Taxes on Income

12 Months Ended

Dec. 31, 2022

Taxes on Income [Abstract]

TAXES ON INCOME

NOTE 8:- TAXES ON INCOME

Income tax rates applicable to the Company in 2021 and 2020 was 21%.

Foreign income tax:

Income tax rates:

Presented hereunder are the income tax rates relevant to the Company’s Israeli subsidiary

2021 - 23%

2020 - 23%

The Company’s Israeli subsidiary have estimated total available carryforward operating tax losses for Israeli income tax purposes of approximately $XX as of December 31, 2022.

Deferred income taxes:

	As of December 31,
	2022		2021
Deferred tax assets:
Net operating loss carry forward	$		$	5,746

Deferred tax asset before valuation allowance				1,243
Valuation allowance				(1,243	)

Net deferred tax asset	$	-	$	-

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.

Reconciliation of the theoretical tax expense to the actual tax expense:

	Year ended December 31,
	2022			2021

Net loss, as reported in the consolidated statements of comprehensive loss	$	3,358		$	1,625
Statutory tax rate		21	%		21	%
Computed “expected” tax income		705			341
Valuation allowance		(705	)		(341	)

Taxes on income	$	-		$	-

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 29 R16.htm IDEA: XBRL DOCUMENT

Selected Statements of Comprehensive Loss Data

12 Months Ended

Dec. 31, 2022

Selected Statements of Comprehensive Loss Data [Abstract]

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA

NOTE 9:- SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA

Research and development expenses:

	For the Year Ended December 31
	2022		2021

Subcontractors and consultants	$	551	$	765
Share based compensation		600		-
Laboratory services		27		11

	$	1,178	$	776

General and administrative expenses:

	For the Year Ended December 31
	2022		2021

Professional services	$	289	$	697
Share based compensation		1,690		-
Consulting services		113		120
Rent and office maintenance		9		31
Others		38		5

	$	2,139	$	853

Financial expenses, net:

	For the Year Ended December 31
	2022		2021

Bank fees	$	3	$	2
Exchange rate differences		38		(6	)
Total financial expenses, net	$	41	$	(4	)

XML 30 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

12 Months Ended

Dec. 31, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 10:- SUBSEQUENT EVENTS

In January 2023, the Company issued 255,750 shares of common stock following certain share purchase agreements dated November and December 2022.

XML 31 R18.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2022

General [Abstract]

Basis of presentation:

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).

The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated upon consolidation.

Use of estimate in preparation of financial statements

Use of estimate in preparation of financial statements:

Financial statements in United States dollars

Financial statements in United States dollars:

Cash and cash equivalents

Cash and cash equivalents:

Fair value measurements

Fair value measurements:

Research and development expenses

Research and development expenses:

Research and development expenses are charged to the statements of comprehensive loss as incurred.

Income taxes

Income taxes:

Basic and diluted net loss per share

Basic and diluted net loss per share:

The net loss per share and the weighted average number of shares used in computing basic and diluted net loss per share is as follows:

	For the Year Ended December 31,
	2022			2021
Numerator:
Net loss applicable to common stockholders	$	(3,358	)	$	(1,625	)

Denominator:
Number of shares of common stock used in computing basic and diluted net loss per share		14,341,518			11,171,704
Net loss of shares of common, basic and diluted	$	(0.23	)	$	(0.15	)

Leases

Recently issued accounting pronouncements

XML 32 R19.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

General [Abstract]

Schedule of net loss per share and the weighted average number of shares

	For the Year Ended December 31,
	2022			2021
Numerator:
Net loss applicable to common stockholders	$	(3,358	)	$	(1,625	)

Denominator:
Number of shares of common stock used in computing basic and diluted net loss per share		14,341,518			11,171,704
Net loss of shares of common, basic and diluted	$	(0.23	)	$	(0.15	)

XML 33 R20.htm IDEA: XBRL DOCUMENT

Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2022

Other Current Assets [Abstract]

Schedule of other current assets

	As of December 31,
	2022		2021

Receivables from governmental authorities	$	38	$	92
Prepaid expenses		5		177

	$	43	$	269

XML 34 R21.htm IDEA: XBRL DOCUMENT

Other Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2022

Payables and Accruals [Abstract]

Schedule of other accounts payable and accrued expenses

	As of December 31,
	2022		2021

Account payables	$	72	$	107
Accrued expenses		152		165

	$	224	$	272

XML 35 R22.htm IDEA: XBRL DOCUMENT

Related Parties Balances and Transactions (Tables)

12 Months Ended

Dec. 31, 2022

Schedule of related party balances

	As of December 31,
	2022		2021
Payables to related party - Officers (*)		3		22
		3		22

(*)	Relates to Chief Executive Officer’s and Chief Financial Officer’s services

Schedule of related party transactions

	Year ended December 31,
	2022		2021
Consulting services (*)		113		120
Legal fee (**)		72		75
		185		195

(*)	Including salary expenses to Company’s CEO. For further details on the consulting agreement with Company’s CEO, refer to Note 6d.

(**)	Including legal services provided to Company’s subsidiary by Company’s Chief Financial Officer with respect to an agreement between the Company and its Chief Financial Officer.

(***)

During 2022, Company’s Chief Technology Officer fees and Directors’ fee were $105 and $17, respectively.

(****)

XML 36 R23.htm IDEA: XBRL DOCUMENT

Taxes on Income (Tables)

12 Months Ended

Dec. 31, 2022

Taxes on Income [Abstract]

Schedule of income tax rate

2021 - 23%

2020 - 23%

Schedule of deferred income taxes

	As of December 31,
	2022		2021
Deferred tax assets:
Net operating loss carry forward	$		$	5,746

Deferred tax asset before valuation allowance				1,243
Valuation allowance				(1,243	)

Net deferred tax asset	$	-	$	-

Schedule of reconciling item between the statutory tax rate of the Company and the effective tax rate

	Year ended December 31,
	2022			2021

Net loss, as reported in the consolidated statements of comprehensive loss	$	3,358		$	1,625
Statutory tax rate		21	%		21	%
Computed “expected” tax income		705			341
Valuation allowance		(705	)		(341	)

Taxes on income	$	-		$	-

XML 37 R24.htm IDEA: XBRL DOCUMENT

Selected Statements of Comprehensive Loss Data (Tables)

12 Months Ended

Dec. 31, 2022

Shareholders

Schedule of research and development expenses

	For the Year Ended December 31
	2022		2021

Subcontractors and consultants	$	551	$	765
Share based compensation		600		-
Laboratory services		27		11

	$	1,178	$	776

Schedule of general and administrative expenses

	For the Year Ended December 31
	2022		2021

Professional services	$	289	$	697
Share based compensation		1,690		-
Consulting services		113		120
Rent and office maintenance		9		31
Others		38		5

	$	2,139	$	853

Schedule of financial expenses, net

	For the Year Ended December 31
	2022		2021

Bank fees	$	3	$	2
Exchange rate differences		38		(6	)
Total financial expenses, net	$	41	$	(4	)

XML 38 R25.htm IDEA: XBRL DOCUMENT

General (Details) - USD ($) $ in Thousands		12 Months Ended
General (Details) - USD ($) $ in Thousands	May 14, 2021	Dec. 31, 2022	Dec. 31, 2021	Oct. 08, 2020
General (Details) [Line Items]
Reverse split, description	the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021.
Split combined each shares (in Shares)	100
Common stock shares issued (in Shares)	9,459,253
Issued and outstanding common stock rate	90.00%
Share exchange common stock (in Shares)	1,051,028
Common stock percentage	10.00%
Accumulated deficit (in Dollars)		$ 6,026
Net loss (in Dollars)		(3,358)	$ (1,625)
Net cash used in operating activities (in Dollars)		(759)	(1,419)
Common Stock [Member]
General (Details) [Line Items]
Percentage of issued and outstanding common stock				10.00%
Net loss (in Dollars)
Raphael [Member] \| Common Stock [Member]
General (Details) [Line Items]
Percentage of issued and outstanding common stock				90.00%

XML 39 R26.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net loss applicable to common stockholders	$ (3,358)	$ (1,625)
Denominator:
Number of shares of common stock used in computing basic and diluted net loss per share	14,341,518	11,171,704
Net loss of shares of common, basic and diluted	$ (0.23)	$ (0.15)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

XML 40 R27.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of net loss per share and the weighted average number of shares [Abstract]
Number of shares of common stock used in computing basic and diluted net loss per share	14,341,518	11,171,704
Net loss of shares of common, basic and diluted	$ (0.23)	$ (0.15)

- Definition

+ References

+ Details

XML 41 R28.htm IDEA: XBRL DOCUMENT

Other Current Assets (Details) - Schedule of other current assets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Current Assets [Abstract]
Receivables from governmental authorities	$ 38	$ 92
Prepaid expenses	5	177
Total	$ 43	$ 269

XML 42 R29.htm IDEA: XBRL DOCUMENT

Other Accounts Payable and Accrued Expenses (Details) - Schedule of other accounts payable and accrued expenses - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Accounts Payable and Accrued Expenses [Abstract]
Account payables	$ 72	$ 107
Accrued expenses	152	165
Total accounts payable and accrued expenses	$ 224	$ 272

XML 43 R30.htm IDEA: XBRL DOCUMENT

Contingent Liabilities and Commitments (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			3 Months Ended	12 Months Ended
	Feb. 01, 2022	Jan. 31, 2023	Oct. 31, 2022	Jun. 30, 2019	Mar. 31, 2023	Dec. 31, 2022	Jan. 08, 2023	Dec. 30, 2022
Contingent Liabilities and Commitments (Details) [Line Items]
Rental monthly fee	$ 1
Company paid milestone payments						$ 1,400
Net sales percentage						6.00%
Rambam research agreement paid						$ 1,150
Total cost description			Total cost of the new study will be $800 + $160 (overhead) + VAT (which consist of $700 + VAT pre-clinical lab research cost, $120 + VAT Mouse model for systemic inflammation and $140 + VAT Mouse model for Rheumatoid Arthritis).
Share capital percentage						3.00%
Cash payment						$ 100
Fee percentage						15.00%
Services fee				$ 10
Warrants granted (in Shares)								18,000
Exercise price (in Dollars per share)						$ 1.12
Termination fee						$ 360
Compensation amount						$ 12
Granted shares (in Shares)						1,000,000
Warrants share (in Shares)						1,000,000
Royalty percentage						15.00%
Company's net royalties percentage						15.00%
Common Stock [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Exercise price (in Dollars per share)						$ 1
Subsequent Event [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Rambam research agreement paid					$ 250
Services fee		$ 20
Warrants granted (in Shares)							100,000
Compensation amount		$ 6
Chief Executive Officer [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Warrants granted (in Shares)						1,000,000
Chief Financial Officer [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Termination fee						$ 120
Chief Technology Officer [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Services fee						$ 9
Exercise price (in Dollars per share)						$ 0.01
Granted shares (in Shares)						350,000
Warrants share (in Shares)						990,000
Chief Technology Officer [Member] \| Royalties [Member]
Contingent Liabilities and Commitments (Details) [Line Items]
Exercise price (in Dollars per share)						$ 0.01

XML 44 R31.htm IDEA: XBRL DOCUMENT

Stockolders’ Equity (Details) - USD ($) $ / shares in Units, $ in Thousands												1 Months Ended			3 Months Ended	12 Months Ended
	Nov. 04, 2022	Oct. 26, 2022	Oct. 21, 2022	Sep. 08, 2022	Jul. 27, 2022	Jun. 30, 2022	Jun. 27, 2022	May 02, 2022	Apr. 28, 2022	Mar. 15, 2022	Mar. 02, 2022	Dec. 31, 2022	Sep. 30, 2021	Jan. 31, 2021	Dec. 31, 2021	Dec. 31, 2022	May 14, 2021
Stockolders’ Equity (Details) [Line Items]
Company raised amount (in Dollars)	$ 100		$ 50				$ 50					$ 20	$ 578	$ 578
Issuance cost (in Dollars)									$ 70					52		$ 102
Common stock share issued	80,000		50,000			280,000	35,000	250,000	70,000			15,624,040	1,632,509		12,970,540	15,624,040	9,459,253
Warrants purchase	20,000		50,000			105,000		100,000	100,000			47,250
Exercise price per share (in Dollars per share)	$ 1.5		$ 1.4			$ 1.12		$ 1.13	$ 0.5			$ 1.25				$ 1.25
Company’s service provider consideration of past services (in Dollars)								$ 250
Equity investment (in Dollars)									$ 550
Exercisable year								2 years
Service fees (in Dollars)				$ 100	$ 100	$ 290
Share issued		90,000		102,000
Warrants outstanding												4,461,250				4,461,250
Common shares issued					100,500
Warrants exercise		90,000
Consideration amount (in Dollars)		$ 100
Common Stock [Member]
Stockolders’ Equity (Details) [Line Items]
Company raised amount (in Dollars)									$ 50		$ 10
Common stock share issued									300,000	270,000	50,000	15,750				15,750	1,051,028
Warrants purchase									100,000	180,000	30,000
Exercise price per share (in Dollars per share)									$ 0.7	$ 1.13	$ 1.25
Company’s service provider consideration of past services (in Dollars)										$ 150
Share issued					1,000,000
Common shares issued				56,000
Total consideration for purchase (in Dollars)				$ 63
Minimum [Member]
Stockolders’ Equity (Details) [Line Items]
Amount received (in Dollars)														$ 160
Exercise price per share (in Dollars per share)												$ 1.12				$ 1.12
Maximum [Member]
Stockolders’ Equity (Details) [Line Items]
Amount received (in Dollars)													$ 470
Exercise price per share (in Dollars per share)												$ 1.25				$ 1.25
Raphael [Member]
Stockolders’ Equity (Details) [Line Items]
Holders percentage																	90.00%
Raphael [Member] \| Common Stock [Member]
Stockolders’ Equity (Details) [Line Items]
Holders percentage																	10.00%
Private Placement [Member]
Stockolders’ Equity (Details) [Line Items]
Company raised amount (in Dollars)															$ 820
Common stock share issued															715,250
Warrants purchase															441,000
Investors [Member]
Stockolders’ Equity (Details) [Line Items]
Company raised amount (in Dollars)								$ 250				$ 200
Common stock share issued								250,000				160,000				160,000
Warrants purchase								100,000				40,000
Exercise price per share (in Dollars per share)								$ 1.13				$ 1.5				$ 1.5
Chief Financial Officer [Member]
Stockolders’ Equity (Details) [Line Items]
Warrants outstanding					1,000,000
Executive Officers [Member]
Stockolders’ Equity (Details) [Line Items]
Service fees (in Dollars)					$ 1,800
Warrants outstanding					2,201,000
Third Party [Member]
Stockolders’ Equity (Details) [Line Items]
Common stock share issued												112,500				112,500

XML 45 R32.htm IDEA: XBRL DOCUMENT

Related Parties Balances and Transactions (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Related Parties Balances and Transactions (Details) [Line Items]
Share based compensation expenses	$ 2,090
Chief Technology Officer [Member]
Related Parties Balances and Transactions (Details) [Line Items]
Share based compensation expenses	105
Director [Member]
Related Parties Balances and Transactions (Details) [Line Items]
Share based compensation expenses	17
Chief Executive Officer [Member]
Related Parties Balances and Transactions (Details) [Line Items]
Share based compensation expenses	250
Chief Financial Officer [Member]
Related Parties Balances and Transactions (Details) [Line Items]
Share based compensation expenses	1,000
Chief Technology Officer and Director [Member]
Related Parties Balances and Transactions (Details) [Line Items]
Share based compensation expenses	500
Current Director [Member]
Related Parties Balances and Transactions (Details) [Line Items]
Share based compensation expenses	50
Former Director [Member]
Related Parties Balances and Transactions (Details) [Line Items]
Share based compensation expenses	$ 290

XML 46 R33.htm IDEA: XBRL DOCUMENT

Related Parties Balances and Transactions (Details) - Schedule of related party balances - USD ($)
$ in Thousands

Dec. 31, 2022

Dec. 31, 2021

Payables to related party - Officers

^[1]

$ 3

$ 22

Total Payables to related party

$ 3

$ 22

[1]	Relates to Chief Executive Officer’s and Chief Financial Officer’s services

XML 47 R34.htm IDEA: XBRL DOCUMENT

Related Parties Balances and Transactions (Details) - Schedule of related party transactions - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Consulting services

^[1]

$ 113

$ 120

Legal fee

^[2]

Total related party transactions

$ 185

$ 195

[1]	Including salary expenses to Company’s CEO and Chief Financial Officer. For further details on the consulting agreement with Company’s CEO, refer to Note 6d.
[2]	Including legal services provided to Company’s subsidiary by Company’s Chief Financial Officer with respect to an agreement between the Company and its Chief Financial Officer.

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

XML 48 R35.htm IDEA: XBRL DOCUMENT

Taxes on Income (Details) - USD ($)	12 Months Ended
Taxes on Income (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Taxes on Income (Details) [Line Items]
Income tax rates		21.00%	21.00%
Net operating loss carryforwards (in Dollars)
Taxable income	80.00%
Ownership [Member]
Taxes on Income (Details) [Line Items]
Ownership interest	50.00%

XML 49 R36.htm IDEA: XBRL DOCUMENT

Taxes on Income (Details) - Schedule of income tax rate	12 Months Ended
Taxes on Income (Details) - Schedule of income tax rate	Dec. 31, 2021	Dec. 31, 2020
ISRAEL
Taxes on Income (Details) - Schedule of income tax rate [Line Items]
Income tax rates	23.00%	23.00%

XML 50 R37.htm IDEA: XBRL DOCUMENT

Taxes on Income (Details) - Schedule of deferred income taxes - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carry forward		$ 5,746
Deferred tax asset before valuation allowance		1,243
Valuation allowance		(1,243)
Net deferred tax asset

XML 51 R38.htm IDEA: XBRL DOCUMENT

Taxes on Income (Details) - Schedule of reconciling item between the statutory tax rate of the Company and the effective tax rate - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Reconciling the Statutory Tax Rate of the Company and the Effective Tax Rate [Abstract]
Net loss, as reported in the consolidated statements of comprehensive loss	$ 3,358	$ 1,625
Statutory tax rate	21.00%	21.00%
Computed “expected” tax income	$ 705	$ 341
Valuation allowance	(705)	(341)
Taxes on income

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 52 R39.htm IDEA: XBRL DOCUMENT

Selected Statements of Comprehensive Loss Data (Details) - Schedule of research and development expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Research and Development Expenses [Abstract]
Subcontractors and consultants	$ 551	$ 765
Share based compensation	600
Laboratory services	27	11
Total	$ 1,178	$ 776

XML 53 R40.htm IDEA: XBRL DOCUMENT

Selected Statements of Comprehensive Loss Data (Details) - Schedule of general and administrative expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of General and Administrative Expenses [Abstract]
Professional services	$ 289	$ 697
Share based compensation	1,690
Consulting services	113	120
Rent and office maintenance	9	31
Others	38	5
Total general and administrative expenses	$ 2,139	$ 853

XML 54 R41.htm IDEA: XBRL DOCUMENT

Selected Statements of Comprehensive Loss Data (Details) - Schedule of financial expenses, net - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of Financial Expenses Net [Abstract]
Bank fees	$ 3	$ 2
Exchange rate differences	38	(6)
Total financial expenses, net	$ 41	$ (4)

XML 55 R42.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) - USD ($)		1 Months Ended
Subsequent Events (Details) - USD ($)	Jan. 08, 2023	Dec. 30, 2022	Jan. 31, 2023
Subsequent Events (Details) [Line Items]
Shares issued		6,000
Agreement amount (in Dollars)		$ 7.5
Warrants share		18,000
Exercise price (in Dollars per share)		$ 1.25
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Shares issued	250,000		255,750
Agreement amount (in Dollars)	$ 250
Warrants share	100,000
Exercise price (in Dollars per share)	$ 1.13

XML 56 f10k2022a1_raphaelpharma_htm.xml IDEA: XBRL DOCUMENT 0001415397 2022-01-01 2022-12-31 0001415397 2023-03-25 0001415397 2022-06-30 0001415397 2022-12-31 0001415397 2021-12-31 0001415397 2021-01-01 2021-12-31 0001415397 us-gaap:CommonStockMember 2021-12-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001415397 us-gaap:RetainedEarningsMember 2021-12-31 0001415397 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001415397 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001415397 us-gaap:CommonStockMember 2022-12-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001415397 us-gaap:RetainedEarningsMember 2022-12-31 0001415397 us-gaap:CommonStockMember 2020-12-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001415397 us-gaap:RetainedEarningsMember 2020-12-31 0001415397 2020-12-31 0001415397 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001415397 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001415397 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001415397 cik0000141539:RaphaelMember us-gaap:CommonStockMember 2020-10-08 0001415397 us-gaap:CommonStockMember 2020-10-08 0001415397 2021-05-01 2021-05-14 0001415397 2021-05-14 0001415397 2022-02-01 2022-02-01 0001415397 us-gaap:SubsequentEventMember 2023-01-01 2023-03-31 0001415397 2022-10-01 2022-10-31 0001415397 us-gaap:SubsequentEventMember 2023-01-01 2023-01-31 0001415397 2019-06-01 2019-06-30 0001415397 srt:ChiefExecutiveOfficerMember 2022-12-31 0001415397 us-gaap:SubsequentEventMember 2023-01-31 0001415397 srt:ChiefFinancialOfficerMember 2022-12-31 0001415397 cik0000141539:ChiefTechnologyOfficerMember 2022-01-01 2022-12-31 0001415397 cik0000141539:ChiefTechnologyOfficerMember 2022-12-31 0001415397 cik0000141539:ChiefTechnologyOfficerMember us-gaap:RoyaltyAgreementTermsMember 2022-01-01 2022-12-31 0001415397 2021-01-01 2021-01-31 0001415397 2021-09-01 2021-09-30 0001415397 2021-09-30 0001415397 srt:MinimumMember 2021-01-01 2021-01-31 0001415397 srt:MaximumMember 2021-09-01 2021-09-30 0001415397 cik0000141539:RaphaelMember 2021-05-14 0001415397 us-gaap:CommonStockMember 2021-05-14 0001415397 cik0000141539:RaphaelMember us-gaap:CommonStockMember 2021-05-14 0001415397 us-gaap:PrivatePlacementMember 2021-10-01 2021-12-31 0001415397 us-gaap:PrivatePlacementMember 2021-12-31 0001415397 srt:MinimumMember 2022-12-31 0001415397 srt:MaximumMember 2022-12-31 0001415397 cik0000141539:ThirdPartiesMember 2022-12-31 0001415397 us-gaap:CommonStockMember 2022-03-01 2022-03-02 0001415397 us-gaap:CommonStockMember 2022-03-02 0001415397 us-gaap:CommonStockMember 2022-03-15 0001415397 us-gaap:CommonStockMember 2022-03-01 2022-03-15 0001415397 us-gaap:CommonStockMember 2022-04-28 2022-04-28 0001415397 us-gaap:CommonStockMember 2022-04-28 0001415397 2022-04-28 0001415397 2022-04-28 2022-04-28 0001415397 cik0000141539:InvestorsMember 2022-04-22 2022-05-02 0001415397 cik0000141539:InvestorsMember 2022-05-02 0001415397 2022-05-02 0001415397 2022-04-22 2022-05-02 0001415397 2022-06-27 2022-06-27 0001415397 2022-06-27 0001415397 2022-06-30 2022-06-30 0001415397 us-gaap:CommonStockMember 2022-07-27 0001415397 srt:ChiefFinancialOfficerMember 2022-07-27 0001415397 srt:ChiefExecutiveOfficerMember 2022-07-27 0001415397 srt:ChiefExecutiveOfficerMember 2022-07-27 2022-07-27 0001415397 2022-07-27 0001415397 2022-07-27 2022-07-27 0001415397 us-gaap:CommonStockMember 2022-09-08 0001415397 us-gaap:CommonStockMember 2022-09-01 2022-09-08 0001415397 2022-09-08 0001415397 2022-09-01 2022-09-08 0001415397 2022-10-21 2022-10-21 0001415397 2022-10-21 0001415397 2022-10-26 0001415397 2022-10-26 2022-10-26 0001415397 2022-11-04 2022-11-04 0001415397 2022-11-04 0001415397 2022-12-01 2022-12-31 0001415397 cik0000141539:InvestorsMember 2022-12-01 2022-12-31 0001415397 cik0000141539:InvestorsMember 2022-12-31 0001415397 srt:ChiefOperatingOfficerMember 2022-01-01 2022-12-31 0001415397 srt:DirectorMember 2022-01-01 2022-12-31 0001415397 srt:ChiefExecutiveOfficerMember 2022-01-01 2022-12-31 0001415397 srt:ChiefFinancialOfficerMember 2022-01-01 2022-12-31 0001415397 cik0000141539:CurrentDirectorMember 2022-01-01 2022-12-31 0001415397 cik0000141539:FormerDirectorMember 2022-01-01 2022-12-31 0001415397 2020-01-01 2020-12-31 0001415397 cik0000141539:OwnershipMember 2022-12-31 0001415397 country:IL 2021-01-01 2021-12-31 0001415397 country:IL 2020-01-01 2020-12-31 0001415397 2022-12-01 2022-12-30 0001415397 2022-12-30 0001415397 us-gaap:SubsequentEventMember 2023-01-01 2023-01-08 0001415397 us-gaap:SubsequentEventMember 2023-01-08 shares iso4217:USD iso4217:USD shares pure 10-K/A true 2022-12-31 --12-31 2022 false 000-53002 Raphael Pharmaceutical Inc. NV 26-0204284 4 Lui Paster Tel Aviv-Jaffa IL 6803605 (972) 52-775-5072 Common Stock, $0.01 par value No No Yes Yes Non-accelerated Filer true false false false 16135790 Raphael Pharmaceutics Inc. (the “Company”) is filing this Amendment No. 1 (the “Amendment”) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 24, 2023 (the “Original Filing”), for the sole purpose of amending and restating the disclosure provided in Item 9 of Part II and including the audit letter of Brightman Almagor Zohar & Co., a firm in the Deloitte global network (the “Former Auditor”), in Item 15 of Part IV, which were inadvertently omitted from the Original Filing.In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the certifications pursuant to Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 have been re-executed as of the date of, and are re-filed as part of, this Amendment as Exhibits 12.1, 12.2, 13.1 and 13.2.Other than expressly set forth herein, this Amendment does not reflect events occurring after the date of the filing of the Original Filing or modify or update any of the other disclosures contained therein in any way. 6629 Brightman Almagor Zohar & Co Tel Aviv, Israel

288000

153000

43000

269000

331000

422000

2000

333000

422000

224000

272000

3000

22000

227000

294000

0.01

15624040

12970540

157000

130000

5975000

2665000

-6026000

-2667000

106000

128000

333000

422000

1178000

776000

2139000

853000

-3317000

-1629000

-41000

4000

-3358000

-1625000

0.23

0.15

14341518

11171704

12970540

130000

2666000

-2668000

128000

831000

8000

885000

893000

1822500

19000

2424000

2443000

-3358000

15624040

157000

5975000

-6026000

106000

9459253

95000

905000

-1043000

-43000

2460259

25000

1265000

1290000

1051028

10000

496000

506000

-1625000

12970540

130000

2666000

-2668000

128000

-3358000

-1625000

2290000

-226000

41000

-19000

13000

102000

234000

-759000

-1419000

2000

-2000

174000

896000 1290000 13000

896000

1477000

135000

58000

153000

95000

288000

153000

150000

70000 102000 -531000 38000 506000 13000

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1:- GENERAL</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Raphael Pharmaceutical Inc (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel. From April 1, 2011 until December 31, 2019, the Company was not active.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021. The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding Common stock into one share of common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2021, Raphael and the Company, completed the Share Exchange pursuant to which 9,459,253 common stock were issued to the shareholders of Raphael so that they became the holders of 90% of the issued and outstanding common stock of the Company immediately after the Share Exchange while the Company’s shareholders hold, following the Share Exchange, 1,051,028 common stock which represents 10% of the Company. On May 19, 2021, as agreed by the parties to the Share Exchange, the Company changed its name to Raphael Pharmaceutical Inc. Following such Share Exchange, Raphael’s activities are the sole activities of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company’s common stock began public trading on the over the counter market in the U.S. in January 2023 under the symbol “RAPH”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p></td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going concern and management plans</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, and raising capital. The Company is still in its development and pre-clinical stage and has not yet generated revenues. The extent of the Company’s future operating losses and the timing of becoming profitable are uncertain. As of December 31, 2022, the Company’s accumulated deficit was $6,026, the net loss for the year then ended was $3,358 and the net cash used in operating activities was $759.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company has funded its operations to date primarily through equity financing.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Management’s plans include, but are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or at all.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists in the event that additional funding does not occur. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.</p>

0.90 0.10

the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021.

100

9459253

0.90

1051028

0.10 6026000

-3358000

-759000

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of presentation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated upon consolidation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimate in preparation of financial statements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial statements in United States dollars:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company’s functional currency is the U.S. dollar (“dollar” or “$”) since the dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future. Transactions and balances denominated in dollars are presented at their original amounts. Transactions and balances denominated in currencies other than dollars have been re-measured to dollars. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in currencies other than dollars are reflected in the statements of comprehensive loss as financial expenses, net.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less as of the date acquired and that are exposed to insignificant risk of change in value.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurements:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The carrying values of Company’s financial assets and liabilities, including cash and cash equivalents, other current assets, related parties, accounts payable and accrued expenses approximate their fair value due to the short-term maturity of these instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 67px"> </td> <td style="width: 29px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Research and development expenses are charged to the statements of comprehensive loss as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company accounts for income taxes in accordance with ASC 740, “Income Taxes”. ASC 740 prescribes the use of the liability method whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more likely than not to be realized. As of December 31, 2022, and 2021, the Company had a full valuation allowance on its deferred tax assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Earnings or loss per share (“EPS”) is the amount of earnings attributable to each share of common stock. For convenience, the term is used to refer to either earnings or loss per share. EPS is computed pursuant to ASC 260-10-45. Pursuant to ASC 260-10-45-10 through 260-10-45-16 Basic EPS is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Loss available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock (whether or not paid) from loss from operating loss (if that amount appears in the statements of comprehensive loss) and also from net loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common stock had been issued during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The net loss per share and the weighted average number of shares used in computing basic and diluted net loss per share is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss applicable to common stockholders</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,358</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,625</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-indent: -9pt; padding-left: 9pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Denominator:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-24; -sec-ix-hidden: hidden-fact-23">Number of shares of common stock used in computing basic and diluted net loss per share</div></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,341,518</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,171,704</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-26; -sec-ix-hidden: hidden-fact-25">Net loss of shares of common, basic and diluted</div></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92.7pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 requires lessees to recognize their leases contracts as assets and liabilities in the financial statements. Furthermore, the ASU requires the Company to continue recognizing expenses but recognize expenses on their statements of comprehensive loss in a manner similar to current lease accounting. The amendments in this ASU are effective January 1, 2019. In July 2018, the FASB issued ASU 2018-11, Leases - Targeted Improvements, to allow a company to elect an optional modified retrospective transition method that applies the new lease requirements through a cumulative-effect adjustment in the period of adoption.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Effective January 2019, the Company adopted the new lease accounting standard. The Company elected to apply the practical expedients permitted under the transition guidance within the new standard. As such, there was no impact on the Company’s financial statements as a result of adopting ASU 2016-02. See note 6a for more details.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently issued accounting pronouncements</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In June 2016, the FASB issued ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). ASU 2016-13 replaces the current incurred loss model guidance with a new method that reflects expected credit losses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under this guidance, an entity would recognize an allowance for credit losses equal to its estimate of expected credit losses on financial assets measured at amortized cost. In November 2019, the FASB extended the effective date of ASU 2016-13 for smaller reporting companies. As a result, ASU 2016-13 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2022, with early adoption permitted. The standard did not have a significant impact on the Company’s consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In May 2021, the Financial Accountings Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-04, “Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815- 40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”). The guidance is effective for the Company on January 1, 2022. The standard did not have a significant impact on the Company’s consolidated financial statements.</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 67px"> </td> <td style="width: 29px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Research and development expenses are charged to the statements of comprehensive loss as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Earnings or loss per share (“EPS”) is the amount of earnings attributable to each share of common stock. For convenience, the term is used to refer to either earnings or loss per share. EPS is computed pursuant to ASC 260-10-45. Pursuant to ASC 260-10-45-10 through 260-10-45-16 Basic EPS is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Loss available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock (whether or not paid) from loss from operating loss (if that amount appears in the statements of comprehensive loss) and also from net loss.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common stock had been issued during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The net loss per share and the weighted average number of shares used in computing basic and diluted net loss per share is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss applicable to common stockholders</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,358</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,625</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-indent: -9pt; padding-left: 9pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Denominator:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-24; -sec-ix-hidden: hidden-fact-23">Number of shares of common stock used in computing basic and diluted net loss per share</div></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,341,518</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,171,704</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-26; -sec-ix-hidden: hidden-fact-25">Net loss of shares of common, basic and diluted</div></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Numerator:</td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss applicable to common stockholders</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,358</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,625</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; text-indent: -9pt; padding-left: 9pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 9pt">Denominator:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-24; -sec-ix-hidden: hidden-fact-23">Number of shares of common stock used in computing basic and diluted net loss per share</div></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,341,518</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,171,704</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-26; -sec-ix-hidden: hidden-fact-25">Net loss of shares of common, basic and diluted</div></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.15</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p>

-3358000

-1625000

14341518

11171704

0.23

0.15

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 3:- OTHER CURRENT ASSETS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Receivables from governmental authorities</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">38</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">92</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">177</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; padding-bottom: 4pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">43</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">269</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Receivables from governmental authorities</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">38</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">92</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Prepaid expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">177</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; padding-bottom: 4pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">43</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">269</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

38000

92000

5000

177000

43000

269000

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 4:- OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Account payables</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">107</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">152</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">165</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; padding-bottom: 4pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">224</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">272</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="2" style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Account payables</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">72</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">107</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">152</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">165</td><td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-size: 10pt; padding-bottom: 4pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">224</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">272</td><td style="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

72000

107000

152000

165000

224000

272000

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 5:- CONTINGENT LIABILITIES AND COMMITMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease commitments:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Starting February 1, 2022, the Company began renting its offices from a third party for a rental monthly fee of approximately $1 per month. The rent period is for a period of one month which renews on a monthly basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company elected to apply the practical expedients permitted under the transition guidance within the new standard, and the Company also elected not to apply the recognition requirements in the lease standard to short-term leases (less than 12 months) as of the adoption date. As such, there was no impact on the Company’s financial statements as a result of adopting ASU 2016-02.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rambam research agreement</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company’s research and development efforts relating to its COVID-19 and rheumatoid arthritis (“RA”) product candidates are being conducted by Rambam Med-Tech Ltd., or Rambam MT, a part of the Rambam Health Care Campus in Israel, in accordance with a Sponsored Research Agreement (the “Research Agreement”), that was entered into by the Company and Rambam MT in July 2019, to be in effect for a period of 48 months and which includes a non-compete extension option for an additional 48 months of research and development. Pursuant to the Research Agreement, the Company agreed to pay Rambam MT $1.4 million in four equal milestone payments, due on the first day of August on each successive year from 2019 through 2022. Furthermore, in accordance with the terms of the Research Agreement, the Company and Rambam MT will have joint ownership of any IP created as a result of research programs covered by such agreement. In addition, subject to commercial sales of any product candidate using the IP created as a part of the research covered by the Research Agreement, the Company is required to pay Rambam MT a royalty in an amount equal to 6% of all net sales, subject to certain deductions, such as taxes paid by any purchaser, transportation and shipping costs, and other customary deductions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2022 the Company paid $1.15 million and in the first quarter of 2023 the Company paid the remaining $0.25 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In October 2022, the Company and Rambam signed an appendix to the Research Agreement, according to which the objective of the new study will be to identify a novel cannabinoid based patentable formulation to treat Rheumatoid diseases. Total cost of the new study will be $800 + $160 (overhead) + VAT (which consist of $700 + VAT pre-clinical lab research cost, $120 + VAT Mouse model for systemic inflammation and $140 + VAT Mouse model for Rheumatoid Arthritis). The Company’s payments will be according to the payment schedule stipulated in the appendix and will begin in May 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Way of Life Cannabis research agreement</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In October 2020, Raphael Israel entered into an engagement agreement with Wolc, pursuant to which, subject to its completing the Share Exchange with Easy Energy, Raphael Israel will be provided with up to 15 liters of CBD oil, from a strain of cannabis during a term of 18 months, to be provided in two to three deliveries of between one to seven liters of CBD oil.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In accordance with Raphael Israel’s agreement with Wolc, Raphael Israel has agreed to issue to certain persons affiliated with Wolc 3% of Raphael’s issued and outstanding share capital as of the date of the Share Exchange, to be provided in three equal issuances; provided, however, that such persons may elect to receive a cash payment of $100 instead of any one issuance of Raphael’s shares. In addition to the issuance of shares, Raphael Israel has also agreed to pay Wolc a royalty fee equal to 15% of the net royalties generated from sales of Raphael Israel’s pharmaceutical drug products that are developed at Rambam hospital in Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In February 2023 the Company and Wolc signed an appendix to the agreement, refer to Note 11d.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting agreement executive officers:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On July 5, 2022 the Company singed several agreements with it’s executive officers:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 1.25in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service agreement with Chief Executive Officer– the Company entered into an agreement with Sheffa Enterprises Inc, a company wholly owned by the Company’s Chief Executive Officer (“CEO”). According to the terms of the agreement, the CEO will provide services to the Company until December 31, 2024 (“termination date”). The fees for his services will be $20 per month starting January 2023 (until January 2023, the fee will remain to be $10 according to a consultant agreement dated June 2019). In addition, the CEO was granted with 1,000,000 warrants to purchase common stock at an exercise price of $1.12 per share. The warrants exercisable until December 31, 2025. Furthermore, the Company may terminate the agreement prior to the termination date by providing 120 days’ advance written notice and paying the CEO a termination fee equal to the lesser of $360 or the monthly fee agreed, for the remaining term of the agreement.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 1.25in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service agreement with Chief Financial Officer– The services will consist of financial services, legal advice and serve as a director of the Company. Base compensation will be $12 starting January 2023 (between July 2022 and January 2023 the base compensation will be $6). In addition, the CFO was granted with 1,000,000 shares of common stock at no cost and 1,000,000 warrants to purchase common stock at an exercise price of $1 per share. The warrants exercisable until December 31, 2025. The agreement is in place until December 31, 2024 (“termination date”). Furthermore, the Company may terminate the agreement prior to the termination date by providing 120 days’ advance written notice and paying the CFO a termination fee equal to the lesser of $120 or the monthly fee agreed, for the remaining term of the agreement.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 1.25in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting agreement with the Chief Technology Officer - the Company entered into an amendment agreement with its Chief Technology Officer (“CTO”). The fees for his services will be $9 per month with the last payment being due and payable on December 31, 2022. According to the terms of the agreement, the CTO will provide consulting services to the Company until December 31, 2023 (“termination date”). In addition, the CTO was granted with 990,000 warrants to purchase common stock at an exercise price of $0.01 per share. The warrants exercisable until July 5, 2024.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 114pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 1.5in; text-align: justify">Furthermore, the CTO will receive 15% of the Company’s net royalties’ from worldwide sales of any of the Company’s cannabis-based medical indications treating COVID-19, and will receive 15% of the net royalty’s income the Company will get for its medical cannabis indication molecules based, for treating Rheumatoid Arthritis (RA) once the Company starts generating revenues. The CTO will be granted with additional 350,000 warrants to purchase common stock at an exercise price of $0.01 per share if the Company will apply for any clinical trial of cannabis based treatment, or will begin any other new cannabis related research. Furthermore, the Company may terminate the agreement prior to the termination date by providing 120 days’ advance written notice and paying the CTO a termination fee equal to the fees that were paid or payables to him for three years pursuant to this agreement.</p>

1000

1400000 0.06

1150000

250000

Total cost of the new study will be $800 + $160 (overhead) + VAT (which consist of $700 + VAT pre-clinical lab research cost, $120 + VAT Mouse model for systemic inflammation and $140 + VAT Mouse model for Rheumatoid Arthritis).

0.03

100000

0.15

20000 10000

1000000

1.12

360000

12000

6000

1000000

120000

9000

990000

0.01

0.15 0.15

350000

0.01

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 6:- STOCKHOLDERS’ EQUITY </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between January and September 2021, the Company raised $578 (net of issuance expenses of $52) and issued 1,632,509 shares of common stock. An amount of $160 was received before the Share Exchange (see Note 1a) and an amount of $470 was received after the Share Exchange.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 14, 2021, the Company, completed a Share Exchange pursuant to which the Company issued 9,459,253 common stock to the shareholders of Raphael, and the shareholders of Raphael became the holders of 90% of the issued and outstanding common stock of the Company while the Company’s shareholders hold, immediately following the Share Exchange, 1,051,028 common stock, which represents 10% of the Company (see also Note 1a).</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October through December 2021, the Company raised $820 and issued 715,250 shares of common stock and 441,000 warrants to purchase common stock in private placement. The warrants are exercisable at an exercise price of $1.12-$1.25 per share into common stock and expire in November and December 2022. As part of the fund raising, the Company issued 112,500 common stock to certain third parties as a finder fee. As such, an amount of $102 was recorded as non cash issuance costs.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 2, 2022, the Company raised $10 and issued 50,000 shares of common stock and 30,000 warrants to purchase common stock at an exercise price of $1.25 per share to certain investors of the Company. The warrants were classified as equity and are exercisable until February 28, 2023.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 15, 2022, the Company issued 270,000 shares of common stock and 180,000 warrants to purchase common stock at an exercise price of $1.13 per share to Company’s service provider in consideration of past services at the amount of $150. The warrants were classified as equity and are exercisable until December 31, 2023.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2022, the Company signed an agreement to raise $50 and to issue 300,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $0.7 per share to certain investor of the Company. The warrants are exercisable until April 30, 2024.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2022 the Company and a certain investor signed a finder fee agreement according to which the Company will issue to the investor 70,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $0.5 per share. The warrants will be exercisable until April 30, 2024. The agreement will become effective once the investor will provide the Company with an equity investment of $550. The shares were issued following May 2022 investment. The value of the shares issued was based on the value of the service provided and amounted to $70 which was recorded as issuance cost.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 2, 2022, the Company signed several agreements to raise $250 and to issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share to certain investors of the Company. The warrants are exercisable until April 30, 2024.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in 0pt 1in; text-align: justify">In addition, it was agreed that the Company will issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share to a certain investor in consideration of additional $250 if the Company’s stock will be publicly traded on the OTC market prior to August 15, 2022. The additional warrants once issued will be exercisable for 2 years. In January 2023 the investor exercised his option for additional investment, refer to Note 11c.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2022, the Company signed an agreement to raise $50 and to issue 35,000 shares of common stock to certain investor of the Company.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2022, the Company issued 280,000 shares of common stock and 105,000 warrants to purchase common stock at an exercise price of $1.12 per share to Company’s former director for his services. The warrants will be exercisable until June 30, 2024. The value of the shares and warrants issued was based on the value of the service provided and amounted to $290.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 27, 2022, the Company issued 1,000,000 shares of common stock and 1,000,000 warrants to Company’s CFO, refer to Note 6d. In addition, the Company issued 2,201,000 warrants to Company’s executive officers and directors pursuant a consultant agreement, refer to Note 6d. The value of the shares and warrants issued was based on the value of the service provided and amounted to $1,800.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 27, 2022, the Company issued 100,500 shares of common stock to Wolc in connection with the services agreement dated October 2020. The value of the shares issued was based on the value of the service provided and amounted to $100.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2022, the Company issued 56,000 shares of common stock to certain investor of the Company pursuant to a share purchase agreement for total consideration of $63.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2022, the Company issued 102,000 shares of common stock to certain service provider of the Company pursuant to consultant agreement. The value of the shares issued was based on the value of the service provided and amounted to $100.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 21, 2022, the Company signed an agreement to raise $50 and to issue 50,000 shares of common stock and 50,000 warrants to purchase common stock at an exercise price of $1.4 per share to certain investor of the Company. The warrants are exercisable until September 30, 2024. The shares of common stock were issued on October 26, 2022.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.65pt; text-align: center"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 26, 2022, the Company issued 90,000 shares of common stock to certain investor of the Company pursuant to an exercise of 90,000 warrants for total consideration of approximately $100.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 4, 2022, the Company signed an agreement to raise $100 and to issue 80,000 shares of common stock and 20,000 warrants to purchase common stock at an exercise price of $1.5 per share to certain investor of the Company. The warrants are exercisable until September 30, 2023. The shares of common stock were issued on January 10, 2023.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2022, the Company signed an agreement to raise $20 and to issue 15,750 shares of common stock and 47,250 warrants to purchase common stock at an exercise price of $1.25 per share to certain investor of the Company. The warrants are exercisable until December 31, 2024. The shares of common stock were issued on January 10, 2023.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2022, the Company signed an agreement to raise $200 and to issue 160,000 shares of common stock and 40,000 warrants to purchase common stock at an exercise price of $1.5 per share to certain investor of the Company. The warrants are exercisable until December 31, 2023. The shares of common stock were issued on January 10, 2023.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0in; text-indent: 1in">As of December 31, 2022, there were 4,461,250 warrants outstanding.</p>

578000 578000

52000

1632509

160000 470000

9459253

0.90

1051028

0.10

820000

715250

441000

1.12

1.25

112500

102000

10000

50000

30000

1.25

270000

180000

1.13

150000 50000

300000

100000

0.7

70000

100000

0.5

550000

70000

250000

100000

1.13

250000

100000

1.13

250000

P2Y

50000

35000

280000

105000

1.12

290000

1000000

2201000

1800000

100500

100000

56000

63000

102000

100000 50000

50000

1.4

90000

100000

80000

20000

1.5

20000

15750

47250

1.25

200000

160000

40000

1.5

4461250

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 7:- RELATED PARTIES BALANCES AND TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balances</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 70.9pt">The following related party payables are included in accounts payable and accrued expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Payables to related party - Officers (*)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">22</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">22</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relates to Chief Executive Officer’s and Chief Financial Officer’s services</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transactions</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Consulting services (*)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Legal fee (**)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">195</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">Including salary expenses to Company’s CEO. For further details on the consulting agreement with Company’s CEO, refer to Note 6d.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(**)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Including legal services provided to Company’s subsidiary by Company’s Chief Financial Officer with respect to an agreement between the Company and its Chief Financial Officer.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(***)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022, Company’s Chief Technology Officer fees and Directors’ fee were $105 and $17, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(****)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, the Company recorded share-based compensation expenses of $2,090, which includes $250 to Company’s CEO, $1,000 to Company’s Chief Financial Officer, $500 to Company’s Chief Technology Officer and Director, $50 to Company’s current director and $290 to Company’s former director, refer to Notes 6d and 7k.</span></td></tr> </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Payables to related party - Officers (*)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">22</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">22</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relates to Chief Executive Officer’s and Chief Financial Officer’s services</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>

3000

22000

3000

22000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Consulting services (*)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">113</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">120</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-align: left">Legal fee (**)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">185</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">195</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(*)</span></td> <td style="text-align: justify"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif">Including salary expenses to Company’s CEO. For further details on the consulting agreement with Company’s CEO, refer to Note 6d.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(**)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Including legal services provided to Company’s subsidiary by Company’s Chief Financial Officer with respect to an agreement between the Company and its Chief Financial Officer.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(***)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022, Company’s Chief Technology Officer fees and Directors’ fee were $105 and $17, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(****)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, the Company recorded share-based compensation expenses of $2,090, which includes $250 to Company’s CEO, $1,000 to Company’s Chief Financial Officer, $500 to Company’s Chief Technology Officer and Director, $50 to Company’s current director and $290 to Company’s former director, refer to Notes 6d and 7k.</span></td></tr> </table>

113000

120000

72000

75000

185000

195000

105000

17000

2090000

250000

1000000

500000

50000

290000

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 8:- TAXES ON INCOME</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 70.9pt">Income tax rates applicable to the Company in 2021 and 2020 was 21%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign income tax:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 1in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax rates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Presented hereunder are the income tax rates relevant to the Company’s Israeli subsidiary</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="width: 100%; padding-left: 0.1pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021 - 23%</span></td></tr> <tr style="vertical-align: top"> <td style="padding-left: 0.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020 - 23%</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-align: justify; text-indent: -28.35pt"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 1in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, the Company had U.S. federal net operating loss carryforwards of approximately <span style="-sec-ix-hidden: hidden-fact-31">$XX</span> available to reduce future taxable income. There is a limitation on the amount of taxable income that can be offset by carryforwards after a change in control (generally greater than a 50% change in ownership). Losses from 2018 and forward that can only offset 80% of taxable income in a future year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s Israeli subsidiary have estimated total available carryforward operating tax losses for Israeli income tax purposes of approximately $XX as of December 31, 2022.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,746</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax asset before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,243</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,243</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences are deductible and net operating losses are utilized. Based on consideration of these factors, the Company recorded a full valuation allowance as of December 31, 2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation of the theoretical tax expense to the actual tax expense:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The main reconciling item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net loss, as reported in the consolidated statements of comprehensive loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,358</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,625</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Statutory tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computed “expected” tax income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">705</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">341</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(705</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(341</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Taxes on income</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

0.21

0.23 0.23

0.50

0.80

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Deferred tax assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,746</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax asset before valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,243</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,243</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Net deferred tax asset</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p>

5746000

1243000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Net loss, as reported in the consolidated statements of comprehensive loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,358</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,625</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Statutory tax rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computed “expected” tax income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">705</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">341</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(705</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(341</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 4pt">Taxes on income</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

3358000

1625000

0.21

705000

341000

-705000

-341000

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9:- SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b> </b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Subcontractors and consultants</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">551</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">765</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Share based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Laboratory services</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">27</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,178</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">776</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative expenses:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b> </b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Professional services</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">289</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">697</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Share based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,690</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Consulting services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Rent and office maintenance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,139</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">853</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial expenses, net:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><b> </b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Bank fees</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Exchange rate differences</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total financial expenses, net</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">41</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table>

600000

27000 11000

1178000

776000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Year Ended<br/> December 31</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Professional services</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">289</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">697</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Share based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,690</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Consulting services</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">113</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">120</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Rent and office maintenance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Others</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,139</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">853</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p>

289000

697000

1690000 113000 120000

9000

31000

38000

5000

2139000

853000

38000

-6000

41000 -4000

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10:- SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2023, the Company issued 255,750 shares of common stock following certain share purchase agreements dated November and December 2022.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.65pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2022, the Company signed an agreement to raise $7.5 and to issue 6,000 shares of common stock and 18,000 warrants to purchase common stock at an exercise price of $1.25 per share to certain investor of the Company. The warrants are exercisable until February 28, 2024. The investment above and share issuance took place in January 2023.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.65pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2023, certain investor of the Company and the Company signed an agreement to raise $250 and to issue 250,000 shares of common stock and 100,000 warrants to purchase common stock at an exercise price of $1.13 per share following the exercise of an option for additional investment (refer to Note 7h). The warrants are exercisable until April 30, 2024.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2023, the Company and Wolc signed an appendix to the research agreement, according to which the parties agreed that Wolc provided to the Company 12 out of 15 liters of CBD oil, from a strain of cannabis and the Company will transfer to Wolc the remaining stock per research agreement. In addition, Wolc will transfer the remaining 3 liters of CBD oil to the Company upon Company’s request.</span></td></tr> </table>

255750

7.5

6000

18000

1.25

250

250000

100000

1.13

0.15

0.23

11171704

14341518

11171704

14341518

0.15

0.23

true FY 0001415397 0

21020560

Number of shares has been retroactively adjusted based on the equivalent number of shares received by the accounting acquirer in the reverse recapitalization transaction and to reflect adjustment to the share par value (refer to Note 1a). Relates to Chief Executive Officer’s and Chief Financial Officer’s services Including salary expenses to Company’s CEO and Chief Financial Officer. For further details on the consulting agreement with Company’s CEO, refer to Note 6d. Including legal services provided to Company’s subsidiary by Company’s Chief Financial Officer with respect to an agreement between the Company and its Chief Financial Officer.

EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 98 202 1 true 21 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement Consolidated Statements of Comprehensive Loss Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals) Sheet http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement_Parentheticals Consolidated Statements of Comprehensive Loss (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Changes Stockholders??? in Equity (Deficit) Sheet http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3 Consolidated Statements of Changes Stockholders??? in Equity (Deficit) Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Cash Flows Sheet http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - General Sheet http://raphaelpharmaceuticalinccom/role/General General Notes 8 false false R9.htm 008 - Disclosure - Significant Accounting Policies Sheet http://raphaelpharmaceuticalinccom/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Other Current Assets Sheet http://raphaelpharmaceuticalinccom/role/OtherCurrentAssets Other Current Assets Notes 10 false false R11.htm 010 - Disclosure - Other Accounts Payable and Accrued Expenses Sheet http://raphaelpharmaceuticalinccom/role/OtherAccountsPayableandAccruedExpenses Other Accounts Payable and Accrued Expenses Notes 11 false false R12.htm 011 - Disclosure - Contingent Liabilities and Commitments Sheet http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitments Contingent Liabilities and Commitments Notes 12 false false R13.htm 012 - Disclosure - Stockolders??? Equity Sheet http://raphaelpharmaceuticalinccom/role/StockoldersEquity Stockolders??? Equity Notes 13 false false R14.htm 013 - Disclosure - Related Parties Balances and Transactions Sheet http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactions Related Parties Balances and Transactions Notes 14 false false R15.htm 014 - Disclosure - Taxes on Income Sheet http://raphaelpharmaceuticalinccom/role/TaxesonIncome Taxes on Income Notes 15 false false R16.htm 015 - Disclosure - Selected Statements of Comprehensive Loss Data Sheet http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossData Selected Statements of Comprehensive Loss Data Notes 16 false false R17.htm 016 - Disclosure - Subsequent Events Sheet http://raphaelpharmaceuticalinccom/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 017 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://raphaelpharmaceuticalinccom/role/SignificantAccountingPolicies 18 false false R19.htm 018 - Disclosure - Significant Accounting Policies (Tables) Sheet http://raphaelpharmaceuticalinccom/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://raphaelpharmaceuticalinccom/role/SignificantAccountingPolicies 19 false false R20.htm 019 - Disclosure - Other Current Assets (Tables) Sheet http://raphaelpharmaceuticalinccom/role/OtherCurrentAssetsTables Other Current Assets (Tables) Tables http://raphaelpharmaceuticalinccom/role/OtherCurrentAssets 20 false false R21.htm 020 - Disclosure - Other Accounts Payable and Accrued Expenses (Tables) Sheet http://raphaelpharmaceuticalinccom/role/OtherAccountsPayableandAccruedExpensesTables Other Accounts Payable and Accrued Expenses (Tables) Tables http://raphaelpharmaceuticalinccom/role/OtherAccountsPayableandAccruedExpenses 21 false false R22.htm 021 - Disclosure - Related Parties Balances and Transactions (Tables) Sheet http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsTables Related Parties Balances and Transactions (Tables) Tables http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactions 22 false false R23.htm 022 - Disclosure - Taxes on Income (Tables) Sheet http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables Taxes on Income (Tables) Tables http://raphaelpharmaceuticalinccom/role/TaxesonIncome 23 false false R24.htm 023 - Disclosure - Selected Statements of Comprehensive Loss Data (Tables) Sheet http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossDataTables Selected Statements of Comprehensive Loss Data (Tables) Tables http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossData 24 false false R25.htm 024 - Disclosure - General (Details) Sheet http://raphaelpharmaceuticalinccom/role/GeneralDetails General (Details) Details http://raphaelpharmaceuticalinccom/role/General 25 false false R26.htm 025 - Disclosure - Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares Details http://raphaelpharmaceuticalinccom/role/SignificantAccountingPoliciesTables 26 false false R27.htm 026 - Disclosure - Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares (Parentheticals) Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable_Parentheticals Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares (Parentheticals) Details http://raphaelpharmaceuticalinccom/role/SignificantAccountingPoliciesTables 27 false false R28.htm 027 - Disclosure - Other Current Assets (Details) - Schedule of other current assets Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofothercurrentassetsTable Other Current Assets (Details) - Schedule of other current assets Details http://raphaelpharmaceuticalinccom/role/OtherCurrentAssetsTables 28 false false R29.htm 028 - Disclosure - Other Accounts Payable and Accrued Expenses (Details) - Schedule of other accounts payable and accrued expenses Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofotheraccountspayableandaccruedexpensesTable Other Accounts Payable and Accrued Expenses (Details) - Schedule of other accounts payable and accrued expenses Details http://raphaelpharmaceuticalinccom/role/OtherAccountsPayableandAccruedExpensesTables 29 false false R30.htm 029 - Disclosure - Contingent Liabilities and Commitments (Details) Sheet http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails Contingent Liabilities and Commitments (Details) Details http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitments 30 false false R31.htm 030 - Disclosure - Stockolders??? Equity (Details) Sheet http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails Stockolders??? Equity (Details) Details http://raphaelpharmaceuticalinccom/role/StockoldersEquity 31 false false R32.htm 031 - Disclosure - Related Parties Balances and Transactions (Details) Sheet http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails Related Parties Balances and Transactions (Details) Details http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsTables 32 false false R33.htm 032 - Disclosure - Related Parties Balances and Transactions (Details) - Schedule of related party balances Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofrelatedpartybalancesTable Related Parties Balances and Transactions (Details) - Schedule of related party balances Details http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsTables 33 false false R34.htm 033 - Disclosure - Related Parties Balances and Transactions (Details) - Schedule of related party transactions Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofrelatedpartytransactionsTable Related Parties Balances and Transactions (Details) - Schedule of related party transactions Details http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsTables 34 false false R35.htm 034 - Disclosure - Taxes on Income (Details) Sheet http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails Taxes on Income (Details) Details http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables 35 false false R36.htm 035 - Disclosure - Taxes on Income (Details) - Schedule of income tax rate Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofincometaxrateTable Taxes on Income (Details) - Schedule of income tax rate Details http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables 36 false false R37.htm 036 - Disclosure - Taxes on Income (Details) - Schedule of deferred income taxes Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofdeferredincometaxesTable Taxes on Income (Details) - Schedule of deferred income taxes Details http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables 37 false false R38.htm 037 - Disclosure - Taxes on Income (Details) - Schedule of reconciling item between the statutory tax rate of the Company and the effective tax rate Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofreconcilingitembetweenthestatutorytaxrateoftheCompanyandtheeffectivetaxrateTable Taxes on Income (Details) - Schedule of reconciling item between the statutory tax rate of the Company and the effective tax rate Details http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables 38 false false R39.htm 038 - Disclosure - Selected Statements of Comprehensive Loss Data (Details) - Schedule of research and development expenses Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofresearchanddevelopmentexpensesTable Selected Statements of Comprehensive Loss Data (Details) - Schedule of research and development expenses Details http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossDataTables 39 false false R40.htm 039 - Disclosure - Selected Statements of Comprehensive Loss Data (Details) - Schedule of general and administrative expenses Sheet http://raphaelpharmaceuticalinccom/role/ScheduleofgeneralandadministrativeexpensesTable Selected Statements of Comprehensive Loss Data (Details) - Schedule of general and administrative expenses Details http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossDataTables 40 false false R41.htm 040 - Disclosure - Selected Statements of Comprehensive Loss Data (Details) - Schedule of financial expenses, net Sheet http://raphaelpharmaceuticalinccom/role/ScheduleoffinancialexpensesnetTable Selected Statements of Comprehensive Loss Data (Details) - Schedule of financial expenses, net Details http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossDataTables 41 false false R42.htm 041 - Disclosure - Subsequent Events (Details) Sheet http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails Subsequent Events (Details) Details http://raphaelpharmaceuticalinccom/role/SubsequentEvents 42 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022a1_raphaelpharma.htm 944, 945 [dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022a1_raphaelpharma.htm 2399, 2400 [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022a1_raphaelpharma.htm 2725, 2726 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 11 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityPublicFloat, us-gaap:CommonStockSharesAuthorized, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10k2022a1_raphaelpharma.htm 3289, 3290, 3291, 3292, 3311, 3312, 3313, 3314, 3326, 3327, 3328 f10k2022a1_raphaelpharma.htm cik0000141539-20221231.xsd cik0000141539-20221231_cal.xml cik0000141539-20221231_def.xml cik0000141539-20221231_lab.xml cik0000141539-20221231_pre.xml f10k2022a1ex31-1_raphael.htm f10k2022a1ex31-2_raphael.htm f10k2022a1ex32-1_raphael.htm f10k2022a1ex32-2_raphael.htm image_001.jpg image_002.jpg image_003.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10k2022a1_raphaelpharma.htm": { "axisCustom": 0, "axisStandard": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 308, "http://xbrl.sec.gov/dei/2022": 35 }, "contextCount": 98, "dts": { "calculationLink": { "local": [ "cik0000141539-20221231_cal.xml" ] }, "definitionLink": { "local": [ "cik0000141539-20221231_def.xml" ] }, "inline": { "local": [ "f10k2022a1_raphaelpharma.htm" ] }, "labelLink": { "local": [ "cik0000141539-20221231_lab.xml" ] }, "presentationLink": { "local": [ "cik0000141539-20221231_pre.xml" ] }, "schema": { "local": [ "cik0000141539-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 309, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 30, "http://raphaelpharmaceuticalinccom/20221231": 6, "http://xbrl.sec.gov/dei/2022": 4, "total": 40 }, "keyCustom": 35, "keyStandard": 167, "memberCustom": 7, "memberStandard": 13, "nsprefix": "cik0000141539", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Other Current Assets", "menuCat": "Notes", "order": "10", "role": "http://raphaelpharmaceuticalinccom/role/OtherCurrentAssets", "shortName": "Other Current Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Other Accounts Payable and Accrued Expenses", "menuCat": "Notes", "order": "11", "role": "http://raphaelpharmaceuticalinccom/role/OtherAccountsPayableandAccruedExpenses", "shortName": "Other Accounts Payable and Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Contingent Liabilities and Commitments", "menuCat": "Notes", "order": "12", "role": "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitments", "shortName": "Contingent Liabilities and Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Stockolders\u2019 Equity", "menuCat": "Notes", "order": "13", "role": "http://raphaelpharmaceuticalinccom/role/StockoldersEquity", "shortName": "Stockolders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Related Parties Balances and Transactions", "menuCat": "Notes", "order": "14", "role": "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactions", "shortName": "Related Parties Balances and Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Taxes on Income", "menuCat": "Notes", "order": "15", "role": "http://raphaelpharmaceuticalinccom/role/TaxesonIncome", "shortName": "Taxes on Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Selected Statements of Comprehensive Loss Data", "menuCat": "Notes", "order": "16", "role": "http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossData", "shortName": "Selected Statements of Comprehensive Loss Data", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "17", "role": "http://raphaelpharmaceuticalinccom/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "18", "role": "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "19", "role": "http://raphaelpharmaceuticalinccom/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Other Current Assets (Tables)", "menuCat": "Tables", "order": "20", "role": "http://raphaelpharmaceuticalinccom/role/OtherCurrentAssetsTables", "shortName": "Other Current Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Other Accounts Payable and Accrued Expenses (Tables)", "menuCat": "Tables", "order": "21", "role": "http://raphaelpharmaceuticalinccom/role/OtherAccountsPayableandAccruedExpensesTables", "shortName": "Other Accounts Payable and Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik0000141539:ScheduleOfRelatedPartyBalancesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Related Parties Balances and Transactions (Tables)", "menuCat": "Tables", "order": "22", "role": "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsTables", "shortName": "Related Parties Balances and Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik0000141539:ScheduleOfRelatedPartyBalancesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Taxes on Income (Tables)", "menuCat": "Tables", "order": "23", "role": "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables", "shortName": "Taxes on Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik0000141539:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Selected Statements of Comprehensive Loss Data (Tables)", "menuCat": "Tables", "order": "24", "role": "http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossDataTables", "shortName": "Selected Statements of Comprehensive Loss Data (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "cik0000141539:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - General (Details)", "menuCat": "Details", "order": "25", "role": "http://raphaelpharmaceuticalinccom/role/GeneralDetails", "shortName": "General (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c24", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares", "menuCat": "Details", "order": "26", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable", "shortName": "Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares (Parentheticals)", "menuCat": "Details", "order": "27", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable_Parentheticals", "shortName": "Significant Accounting Policies (Details) - Schedule of net loss per share and the weighted average number of shares (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ReceivablesFromBrokersDealersAndClearingOrganizations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Other Current Assets (Details) - Schedule of other current assets", "menuCat": "Details", "order": "28", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofothercurrentassetsTable", "shortName": "Other Current Assets (Details) - Schedule of other current assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ReceivablesFromBrokersDealersAndClearingOrganizations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Other Accounts Payable and Accrued Expenses (Details) - Schedule of other accounts payable and accrued expenses", "menuCat": "Details", "order": "29", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofotheraccountspayableandaccruedexpensesTable", "shortName": "Other Accounts Payable and Accrued Expenses (Details) - Schedule of other accounts payable and accrued expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c26", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestAndFeeIncomeLoansAndLeases", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Contingent Liabilities and Commitments (Details)", "menuCat": "Details", "order": "30", "role": "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "shortName": "Contingent Liabilities and Commitments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c26", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestAndFeeIncomeLoansAndLeases", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c79", "decimals": "-3", "first": true, "lang": null, "name": "cik0000141539:CompanyRaisedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Stockolders\u2019 Equity (Details)", "menuCat": "Details", "order": "31", "role": "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails", "shortName": "Stockolders\u2019 Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c79", "decimals": "-3", "first": true, "lang": null, "name": "cik0000141539:CompanyRaisedAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Related Parties Balances and Transactions (Details)", "menuCat": "Details", "order": "32", "role": "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails", "shortName": "Related Parties Balances and Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "cik0000141539:ScheduleOfRelatedPartyBalancesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Related Parties Balances and Transactions (Details) - Schedule of related party balances", "menuCat": "Details", "order": "33", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofrelatedpartybalancesTable", "shortName": "Related Parties Balances and Transactions (Details) - Schedule of related party balances", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "cik0000141539:ScheduleOfRelatedPartyBalancesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherNotesPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Related Parties Balances and Transactions (Details) - Schedule of related party transactions", "menuCat": "Details", "order": "34", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofrelatedpartytransactionsTable", "shortName": "Related Parties Balances and Transactions (Details) - Schedule of related party transactions", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfessionalFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c5", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Taxes on Income (Details)", "menuCat": "Details", "order": "35", "role": "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails", "shortName": "Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c5", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c92", "decimals": "2", "first": true, "lang": null, "name": "cik0000141539:IncomeTaxRates", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Taxes on Income (Details) - Schedule of income tax rate", "menuCat": "Details", "order": "36", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofincometaxrateTable", "shortName": "Taxes on Income (Details) - Schedule of income tax rate", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c92", "decimals": "2", "first": true, "lang": null, "name": "cik0000141539:IncomeTaxRates", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Taxes on Income (Details) - Schedule of deferred income taxes", "menuCat": "Details", "order": "37", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofdeferredincometaxesTable", "shortName": "Taxes on Income (Details) - Schedule of deferred income taxes", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Taxes on Income (Details) - Schedule of reconciling item between the statutory tax rate of the Company and the effective tax rate", "menuCat": "Details", "order": "38", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofreconcilingitembetweenthestatutorytaxrateoftheCompanyandtheeffectivetaxrateTable", "shortName": "Taxes on Income (Details) - Schedule of reconciling item between the statutory tax rate of the Company and the effective tax rate", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "cik0000141539:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "cik0000141539:SubcontractorsAndConsultants1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Selected Statements of Comprehensive Loss Data (Details) - Schedule of research and development expenses", "menuCat": "Details", "order": "39", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofresearchanddevelopmentexpensesTable", "shortName": "Selected Statements of Comprehensive Loss Data (Details) - Schedule of research and development expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "cik0000141539:ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "cik0000141539:SubcontractorsAndConsultants1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "4", "role": "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "cik0000141539:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfessionalAndContractServicesExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Selected Statements of Comprehensive Loss Data (Details) - Schedule of general and administrative expenses", "menuCat": "Details", "order": "40", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleofgeneralandadministrativeexpensesTable", "shortName": "Selected Statements of Comprehensive Loss Data (Details) - Schedule of general and administrative expenses", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "cik0000141539:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfessionalAndContractServicesExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "cik0000141539:ScheduleOfFinancialExpensesNetTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "cik0000141539:BankFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Selected Statements of Comprehensive Loss Data (Details) - Schedule of financial expenses, net", "menuCat": "Details", "order": "41", "role": "http://raphaelpharmaceuticalinccom/role/ScheduleoffinancialexpensesnetTable", "shortName": "Selected Statements of Comprehensive Loss Data (Details) - Schedule of financial expenses, net", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "cik0000141539:ScheduleOfFinancialExpensesNetTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "cik0000141539:BankFees", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c95", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "42", "role": "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c95", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ExcessStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Comprehensive Loss (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Consolidated Statements of Comprehensive Loss (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c15", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Changes Stockholders\u2019 in Equity (Deficit)", "menuCat": "Statements", "order": "6", "role": "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statements of Changes Stockholders\u2019 in Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c15", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - General", "menuCat": "Notes", "order": "8", "role": "http://raphaelpharmaceuticalinccom/role/General", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://raphaelpharmaceuticalinccom/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022a1_raphaelpharma.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 21, "tag": { "cik0000141539_AccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value accumulated deficit.", "label": "Accumulated Deficit", "terseLabel": "Accumulated deficit (in Dollars)" } } }, "localname": "AccumulatedDeficit", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "monetaryItemType" }, "cik0000141539_AgreementAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of agreements.", "label": "Agreement Amount", "terseLabel": "Agreement amount (in Dollars)" } } }, "localname": "AgreementAmount", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "cik0000141539_AmountReceived": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount received from share exchange.", "label": "Amount Received", "terseLabel": "Amount received (in Dollars)" } } }, "localname": "AmountReceived", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cik0000141539_BankFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of bank fee.", "label": "Bank Fees", "terseLabel": "Bank fees" } } }, "localname": "BankFees", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleoffinancialexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "cik0000141539_CashAcquiredInConnectionWithReverseRecapitalizationTransaction": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash acquired in connection with reverse recapitalization transaction.", "label": "Cash Acquired In Connection With Reverse Recapitalization Transaction", "terseLabel": "Cash acquired in connection with reverse recapitalization transaction" } } }, "localname": "CashAcquiredInConnectionWithReverseRecapitalizationTransaction", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cik0000141539_CashAcquiredInTheReverseRecapitalization": { "auth_ref": [], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash flow cash acquired in the reverse recapitalization.", "label": "Cash Acquired In The Reverse Recapitalization", "terseLabel": "Cash acquired in the reverse recapitalization" } } }, "localname": "CashAcquiredInTheReverseRecapitalization", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cik0000141539_CashFlowsFromInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities Abstract", "terseLabel": "Cash flows from investing activities" } } }, "localname": "CashFlowsFromInvestingActivitiesAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "cik0000141539_CashPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash payments.", "label": "Cash Payment", "terseLabel": "Cash payment" } } }, "localname": "CashPayment", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "cik0000141539_ChiefTechnologyOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Technology Officer Member", "terseLabel": "Chief Technology Officer [Member]", "verboseLabel": "Chief Technology Officer and Director [Member]" } } }, "localname": "ChiefTechnologyOfficerMember", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails" ], "xbrltype": "domainItemType" }, "cik0000141539_CommonStockPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock percentage.", "label": "Common Stock Percentage", "terseLabel": "Common stock percentage" } } }, "localname": "CommonStockPercentage", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "percentItemType" }, "cik0000141539_CompanyRaisedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Company raised amount.", "label": "Company Raised Amount", "terseLabel": "Company raised amount (in Dollars)" } } }, "localname": "CompanyRaisedAmount", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cik0000141539_CompanysNetRoyaltiesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Company's net royalties percentage.", "label": "Companys Net Royalties Percentage", "terseLabel": "Company's net royalties percentage" } } }, "localname": "CompanysNetRoyaltiesPercentage", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "percentItemType" }, "cik0000141539_CompanysServiceProviderConsiderationOfPastServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Company\u2019s service provider consideration of past services.", "label": "Companys Service Provider Consideration Of Past Services", "terseLabel": "Company\u2019s service provider consideration of past services (in Dollars)" } } }, "localname": "CompanysServiceProviderConsiderationOfPastServices", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cik0000141539_ConsultingServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of consulting services.", "label": "Consulting Services", "terseLabel": "Consulting services" } } }, "localname": "ConsultingServices", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "cik0000141539_ContingentLiabilitiesandCommitmentsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contingent Liabilities and Commitments (Details) [Line Items]" } } }, "localname": "ContingentLiabilitiesandCommitmentsDetailsLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_ContingentLiabilitiesandCommitmentsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contingent Liabilities and Commitments (Details) [Table]" } } }, "localname": "ContingentLiabilitiesandCommitmentsDetailsTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_CurrentAssetsexcludingCashAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current assets excluding cash and cash equivalents.", "label": "Current Assetsexcluding Cash And Cash Equivalents", "terseLabel": "Current assets (excluding cash and cash equivalents)" } } }, "localname": "CurrentAssetsexcludingCashAndCashEquivalents", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cik0000141539_CurrentDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Director Member", "terseLabel": "Current Director [Member]" } } }, "localname": "CurrentDirectorMember", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails" ], "xbrltype": "domainItemType" }, "cik0000141539_CurrentLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current liabilities.", "label": "Current Liabilities", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cik0000141539_DeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Abstract", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofdeferredincometaxesTable" ], "xbrltype": "stringItemType" }, "cik0000141539_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator Abstract", "terseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable" ], "xbrltype": "stringItemType" }, "cik0000141539_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_EquityMethodInvestmentOwnershipPercentage1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage1", "terseLabel": "Percentage of issued and outstanding common stock" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage1", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "percentItemType" }, "cik0000141539_FormerDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Former Director Member", "terseLabel": "Former Director [Member]" } } }, "localname": "FormerDirectorMember", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails" ], "xbrltype": "domainItemType" }, "cik0000141539_GeneralDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General (Details) [Line Items]" } } }, "localname": "GeneralDetailsLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_GeneralDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General (Details) [Table]" } } }, "localname": "GeneralDetailsTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_GeneralLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General Line Items", "terseLabel": "General [Abstract]" } } }, "localname": "GeneralLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/General" ], "xbrltype": "stringItemType" }, "cik0000141539_GeneralTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General [Table]" } } }, "localname": "GeneralTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/General" ], "xbrltype": "stringItemType" }, "cik0000141539_IncomeTaxRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income tax rates.", "label": "Income Tax Rates", "terseLabel": "Income tax rates" } } }, "localname": "IncomeTaxRates", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofincometaxrateTable" ], "xbrltype": "percentItemType" }, "cik0000141539_InvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investors Member", "terseLabel": "Investors [Member]" } } }, "localname": "InvestorsMember", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "cik0000141539_IssuedAndOutstandingShareCapitalPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued and outstanding share capital percentage.", "label": "Issued And Outstanding Share Capital Percentage", "terseLabel": "Issued and outstanding common stock rate" } } }, "localname": "IssuedAndOutstandingShareCapitalPercentage", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "percentItemType" }, "cik0000141539_LaboratoryServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of laboratory services.", "label": "Laboratory Services", "terseLabel": "Laboratory services" } } }, "localname": "LaboratoryServices", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofresearchanddevelopmentexpensesTable" ], "xbrltype": "monetaryItemType" }, "cik0000141539_MilestonePayment1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of milestone payment.", "label": "Milestone Payment1", "terseLabel": "Company paid milestone payments" } } }, "localname": "MilestonePayment1", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "cik0000141539_NetSalesPercenage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net sales percenage.", "label": "Net Sales Percenage", "terseLabel": "Net sales percentage" } } }, "localname": "NetSalesPercenage", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "percentItemType" }, "cik0000141539_NonCashIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non cash issuance costs.", "label": "Non Cash Issuance Costs", "terseLabel": "Non cash issuance costs (Note 7g)" } } }, "localname": "NonCashIssuanceCosts", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cik0000141539_NonCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non Current Assets Abstract", "terseLabel": "Non-Current assets:" } } }, "localname": "NonCurrentAssetsAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "cik0000141539_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator Abstract", "terseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable" ], "xbrltype": "stringItemType" }, "cik0000141539_OwnershipMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership Member", "terseLabel": "Ownership [Member]" } } }, "localname": "OwnershipMember", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "cik0000141539_ProceedsFromIssuanceOfCommonStockAndWarrants": { "auth_ref": [], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock and warrants.", "label": "Proceeds From Issuance Of Common Stock And Warrants", "terseLabel": "Proceeds from issuance of common stock and warrants" } } }, "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cik0000141539_PurchaseWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The value of purchase warrants.", "label": "Purchase Warrants", "terseLabel": "Warrants purchase" } } }, "localname": "PurchaseWarrants", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "sharesItemType" }, "cik0000141539_RaphaelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Raphael Member", "terseLabel": "Raphael [Member]" } } }, "localname": "RaphaelMember", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails", "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "cik0000141539_RelatedPartiesBalancesandTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Parties Balances and Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartiesBalancesandTransactionsDetailsLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_RelatedPartiesBalancesandTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Parties Balances and Transactions (Details) [Table]" } } }, "localname": "RelatedPartiesBalancesandTransactionsDetailsTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_RemainingServicesFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Company\u2019s service provider consideration of past services.", "label": "Remaining Services Fee", "terseLabel": "Services fee" } } }, "localname": "RemainingServicesFee", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "cik0000141539_ReverseRecapitalizationEffectOnEquity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reverse recapitalization effect on equity.", "label": "Reverse Recapitalization Effect On Equity", "terseLabel": "Reverse recapitalization effect on equity" } } }, "localname": "ReverseRecapitalizationEffectOnEquity", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "cik0000141539_RoyaltyPercentage1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty percentage.", "label": "Royalty Percentage1", "terseLabel": "Royalty percentage" } } }, "localname": "RoyaltyPercentage1", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "percentItemType" }, "cik0000141539_ScheduleOfDeferredIncomeTaxesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Income Taxes [Abstract]" } } }, "localname": "ScheduleOfDeferredIncomeTaxesAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfFinancialExpensesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Financial Expenses Net [Abstract]" } } }, "localname": "ScheduleOfFinancialExpensesNetAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfFinancialExpensesNetTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Financial Expenses Net Table Text Block", "terseLabel": "Schedule of financial expenses, net" } } }, "localname": "ScheduleOfFinancialExpensesNetTableTextBlock", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossDataTables" ], "xbrltype": "textBlockItemType" }, "cik0000141539_ScheduleOfGeneralAndAdministrativeExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of General and Administrative Expenses [Abstract]" } } }, "localname": "ScheduleOfGeneralAndAdministrativeExpensesAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of General And Administrative Expenses Table Text Block", "terseLabel": "Schedule of general and administrative expenses" } } }, "localname": "ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossDataTables" ], "xbrltype": "textBlockItemType" }, "cik0000141539_ScheduleOfIncomeTaxRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Income Tax Rate Abstract" } } }, "localname": "ScheduleOfIncomeTaxRateAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfNetLossPerShareAndTheWeightedAverageNumberOfSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of net loss per share and the weighted average number of shares [Abstract]" } } }, "localname": "ScheduleOfNetLossPerShareAndTheWeightedAverageNumberOfSharesAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfOtherAccountsPayableAndAccruedExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Other Accounts Payable and Accrued Expenses [Abstract]" } } }, "localname": "ScheduleOfOtherAccountsPayableAndAccruedExpensesAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfOtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Abstract]" } } }, "localname": "ScheduleOfOtherCurrentAssetsAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfReconcilingItemBetweenTheStatutoryTaxRateOfTheCompanyAndTheEffectiveTaxRateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Reconciling the Statutory Tax Rate of the Company and the Effective Tax Rate [Abstract]" } } }, "localname": "ScheduleOfReconcilingItemBetweenTheStatutoryTaxRateOfTheCompanyAndTheEffectiveTaxRateAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfRelatedPartyBalancesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Balances [Abstract]" } } }, "localname": "ScheduleOfRelatedPartyBalancesAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfRelatedPartyBalancesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Related Party Balances Table Text Block", "terseLabel": "Schedule of related party balances" } } }, "localname": "ScheduleOfRelatedPartyBalancesTableTextBlock", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsTables" ], "xbrltype": "textBlockItemType" }, "cik0000141539_ScheduleOfRelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Abstract]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfResearchAndDevelopmentExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Research and Development Expenses [Abstract]" } } }, "localname": "ScheduleOfResearchAndDevelopmentExpensesAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "xbrltype": "stringItemType" }, "cik0000141539_ScheduleOfResearchAndDevelopmentExpensesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Research And Development Expenses Table Text Block", "terseLabel": "Schedule of research and development expenses" } } }, "localname": "ScheduleOfResearchAndDevelopmentExpensesTableTextBlock", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossDataTables" ], "xbrltype": "textBlockItemType" }, "cik0000141539_SelectedStatementsofComprehensiveLossDataLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Selected Statements of Comprehensive Loss Data [Abstract]" } } }, "localname": "SelectedStatementsofComprehensiveLossDataLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossData" ], "xbrltype": "stringItemType" }, "cik0000141539_SelectedStatementsofComprehensiveLossDataTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Selected Statements of Comprehensive Loss Data [Table]" } } }, "localname": "SelectedStatementsofComprehensiveLossDataTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossData" ], "xbrltype": "stringItemType" }, "cik0000141539_ServiceFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense in the period for service fees.", "label": "Service Fees", "terseLabel": "Service fees (in Dollars)" } } }, "localname": "ServiceFees", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "monetaryItemType" }, "cik0000141539_ShareBasedCompensation1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of share based compensation.", "label": "Share Based Compensation1", "terseLabel": "Share based compensation" } } }, "localname": "ShareBasedCompensation1", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "cik0000141539_StockholdersEquityDeficitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Deficit Abstract", "terseLabel": "Stockholders\u2019 equity (deficit):" } } }, "localname": "StockholdersEquityDeficitAbstract", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "cik0000141539_StockoldersEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockolders\u2019 Equity (Details) [Line Items]" } } }, "localname": "StockoldersEquityDetailsLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_StockoldersEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockolders\u2019 Equity (Details) [Table]" } } }, "localname": "StockoldersEquityDetailsTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_StockoldersEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockolders\u2019 Equity [Abstract]" } } }, "localname": "StockoldersEquityLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquity" ], "xbrltype": "stringItemType" }, "cik0000141539_StockoldersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockolders\u2019 Equity [Table]" } } }, "localname": "StockoldersEquityTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquity" ], "xbrltype": "stringItemType" }, "cik0000141539_SubcontractorsAndConsultants1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of subcontractors and consultants.", "label": "Subcontractors And Consultants1", "terseLabel": "Subcontractors and consultants" } } }, "localname": "SubcontractorsAndConsultants1", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofresearchanddevelopmentexpensesTable" ], "xbrltype": "monetaryItemType" }, "cik0000141539_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_TaxesonIncomeDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes on Income (Details) [Line Items]" } } }, "localname": "TaxesonIncomeDetailsLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_TaxesonIncomeDetailsScheduleofincometaxrateLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes on Income (Details) - Schedule of income tax rate [Line Items]" } } }, "localname": "TaxesonIncomeDetailsScheduleofincometaxrateLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofincometaxrateTable" ], "xbrltype": "stringItemType" }, "cik0000141539_TaxesonIncomeDetailsScheduleofincometaxrateTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes on Income (Details) - Schedule of income tax rate [Table]" } } }, "localname": "TaxesonIncomeDetailsScheduleofincometaxrateTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofincometaxrateTable" ], "xbrltype": "stringItemType" }, "cik0000141539_TaxesonIncomeDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes on Income (Details) [Table]" } } }, "localname": "TaxesonIncomeDetailsTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_TaxesonIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes on Income [Abstract]" } } }, "localname": "TaxesonIncomeLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncome" ], "xbrltype": "stringItemType" }, "cik0000141539_TaxesonIncomeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes on Income [Table]" } } }, "localname": "TaxesonIncomeTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncome" ], "xbrltype": "stringItemType" }, "cik0000141539_TaxesonIncomeTablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxeson Income Tables Line Items", "terseLabel": "Taxes on Income [Abstract]" } } }, "localname": "TaxesonIncomeTablesLineItems", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables" ], "xbrltype": "stringItemType" }, "cik0000141539_TaxesonIncomeTablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Taxes on Income (Tables) [Table]" } } }, "localname": "TaxesonIncomeTablesTable", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables" ], "xbrltype": "stringItemType" }, "cik0000141539_ThirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Third Parties Member", "terseLabel": "Third Party [Member]" } } }, "localname": "ThirdPartiesMember", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "cik0000141539_TotalCostDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of cost method investments classified as other.", "label": "Total Cost Description", "terseLabel": "Total cost description" } } }, "localname": "TotalCostDescription", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "cik0000141539_TotalFinancialExpensesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total value of financial expenses, net.", "label": "Total Financial Expenses Net", "terseLabel": "Total financial expenses, net" } } }, "localname": "TotalFinancialExpensesNet", "nsuri": "http://raphaelpharmaceuticalinccom/20221231", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleoffinancialexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "country_IL": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ISRAEL", "terseLabel": "ISRAEL" } } }, "localname": "IL", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofincometaxrateTable" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r301", "r302", "r303" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security", "terseLabel": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer [Member]", "verboseLabel": "Executive Officers [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails", "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]", "terseLabel": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails", "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefOperatingOfficerMember": { "auth_ref": [ "r317", "r331" ], "lang": { "en-us": { "role": { "label": "Chief Operating Officer [Member]", "terseLabel": "Chief Technology Officer [Member]" } } }, "localname": "ChiefOperatingOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r154", "r155", "r156", "r157", "r185", "r246", "r269", "r286", "r287", "r291", "r293", "r298", "r323", "r336", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r154", "r155", "r156", "r157", "r185", "r246", "r269", "r286", "r287", "r291", "r293", "r298", "r323", "r336", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r154", "r155", "r156", "r157", "r183", "r185", "r187", "r188", "r189", "r245", "r246", "r269", "r286", "r287", "r291", "r293", "r298", "r319", "r323", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r154", "r155", "r156", "r157", "r183", "r185", "r187", "r188", "r189", "r245", "r246", "r269", "r286", "r287", "r291", "r293", "r298", "r319", "r323", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r147", "r148", "r275", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r292", "r297", "r324" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofincometaxrateTable" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r317", "r331" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails", "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails", "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ScheduleofotheraccountspayableandaccruedexpensesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "Total accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofotheraccountspayableandaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "OTHER ACCOUNTS PAYABLE AND ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/OtherAccountsPayableandAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Other accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r69", "r77" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ScheduleofotheraccountspayableandaccruedexpensesTable": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Account payables" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofotheraccountspayableandaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ScheduleofotheraccountspayableandaccruedexpensesTable": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofotheraccountspayableandaccruedexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r4", "r296" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r190", "r191", "r192", "r313", "r314", "r315", "r329" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Recognition and Exercise", "terseLabel": "Share based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofresearchanddevelopmentexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r65", "r72", "r90", "r109", "r141", "r143", "r145", "r150", "r158", "r159", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r215", "r219", "r225", "r296", "r321", "r322", "r334" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r87", "r93", "r109", "r150", "r158", "r159", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r215", "r219", "r225", "r296", "r321", "r322", "r334" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of presentation:" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r33", "r89", "r288" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r27", "r33", "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at the end of the year", "periodStartLabel": "Cash and cash equivalents at the beginning of the year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r27", "r63" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Change in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants share (in Shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightUnissued": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.", "label": "Class of Warrant or Right, Unissued", "terseLabel": "Warrants granted (in Shares)", "verboseLabel": "Warrants share" } } }, "localname": "ClassOfWarrantOrRightUnissued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Contingent Liabilities and Commitments [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r47", "r152", "r153", "r276", "r320" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r313", "r314", "r329" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "netLabel": "Common stock [Member]", "terseLabel": "Common stock", "verboseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/GeneralDetails", "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3", "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock share issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet_Parentheticals", "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r3", "r48" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r3", "r296" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value:Authorized: 21,020,560 shares;Issued and outstanding: 15,624,040 and 12,970,540 as of December 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndBenefitsTrust": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of a trust established to hold the stock of an employee compensation and benefits plan as of the balance sheet date.", "label": "Compensation and Benefits Trust", "terseLabel": "Compensation amount" } } }, "localname": "CompensationAndBenefitsTrust", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r16", "r95", "r97", "r103", "r262", "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "terseLabel": "Net loss, as reported in the consolidated statements of comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofreconcilingitembetweenthestatutorytaxrateoftheCompanyandtheeffectivetaxrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r23", "r102", "r261", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SelectedStatementsofComprehensiveLossData" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostMaintenance": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.", "label": "Cost, Maintenance", "terseLabel": "Rent and office maintenance" } } }, "localname": "CostMaintenance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Warrants exercise" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Exercisable year" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "terseLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofdeferredincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Deferred tax asset before valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofdeferredincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r61", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carry forward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofdeferredincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r200" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofdeferredincometaxesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Current Assets [Abstract]" } } }, "localname": "DisclosureTextBlockSupplementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r10", "r160", "r161", "r162", "r166", "r167", "r168", "r239", "r312" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Payable to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r104", "r117", "r118", "r119", "r120", "r121", "r125", "r128", "r131", "r132", "r133", "r134", "r223", "r224", "r263", "r267", "r289" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "negatedLabel": "Net loss of shares of common, basic and diluted", "terseLabel": "Basic and diluted net loss per share (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement", "http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r104", "r117", "r118", "r119", "r120", "r121", "r128", "r131", "r132", "r133", "r134", "r223", "r224", "r263", "r267", "r289" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "negatedLabel": "Net loss of shares of common, basic and diluted", "terseLabel": "Basic and diluted net loss per share (in Dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement_Parentheticals", "http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r39", "r40" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r110", "r196", "r208" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofreconcilingitembetweenthestatutorytaxrateoftheCompanyandtheeffectivetaxrateTable" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r325", "r328" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Taxable income" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": { "auth_ref": [ "r325", "r328" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent", "terseLabel": "Income tax rates" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.", "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash", "terseLabel": "Share based compensation expenses" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r48", "r85", "r99", "r100", "r101", "r112", "r113", "r114", "r116", "r122", "r124", "r135", "r151", "r182", "r190", "r191", "r192", "r204", "r205", "r222", "r226", "r227", "r228", "r229", "r230", "r231", "r235", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/GeneralDetails", "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3", "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentAggregateCost": { "auth_ref": [ "r9" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.", "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Equity investment (in Dollars)" } } }, "localname": "EquityMethodInvestmentAggregateCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Holders percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ExcessStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of excess stock shares permitted to be issued.", "label": "Excess Stock, Shares Authorized", "terseLabel": "Common stock shares issued (in Shares)" } } }, "localname": "ExcessStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Shares issued" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r46", "r248" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Fixed asset, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Financial statements in United States dollars" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r20" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r110", "r197", "r198", "r202", "r206", "r209", "r211", "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "TAXES ON INCOME" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r111", "r123", "r124", "r140", "r195", "r207", "r210", "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Taxes on income" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofreconcilingitembetweenthestatutorytaxrateoftheCompanyandtheeffectivetaxrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r98", "r193", "r194", "r198", "r199", "r201", "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofreconcilingitembetweenthestatutorytaxrateoftheCompanyandtheeffectivetaxrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Exchange rate differences" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleoffinancialexpensesnetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r325" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount", "terseLabel": "Computed \u201cexpected\u201d tax income" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofreconcilingitembetweenthestatutorytaxrateoftheCompanyandtheeffectivetaxrateTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r30" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Other accounts payables and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r30" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "terseLabel": "Related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r309" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndFeeIncomeLoansAndLeases": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate interest and fee income generated by: (1) loans the Entity has positive intent and ability to hold for the foreseeable future, or until maturity or payoff, including commercial and consumer loans, whether domestic or foreign, which may consist of: (a) industrial and agricultural; (b) real estate; and (c) real estate construction loans; (d) trade financing; (e) lease financing; (f) home equity lines-of-credit; (g) automobile and other vehicle loans; and (h) credit card and other revolving-type loans and (2) loans and leases held-for-sale which may include mortgage loans, direct financing, and sales-type leases.", "label": "Interest and Fee Income, Loans and Leases", "terseLabel": "Rental monthly fee" } } }, "localname": "InterestAndFeeIncomeLoansAndLeases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Issuance of shares for past services (Note 7e)" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r19" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Legal fee" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofrelatedpartytransactionsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r8", "r67", "r75", "r296", "r310", "r318", "r330" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r14", "r88", "r109", "r150", "r158", "r159", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r216", "r219", "r220", "r225", "r296", "r321", "r334", "r335" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesSubjectToCompromiseEarlyContractTerminationFees": { "auth_ref": [ "r333" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of early contract termination fees included in liabilities subject to compromise.", "label": "Liabilities Subject to Compromise, Early Contract Termination Fees", "terseLabel": "Termination fee" } } }, "localname": "LiabilitiesSubjectToCompromiseEarlyContractTerminationFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Fee percentage" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership interest" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r27", "r29", "r32" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Net cash used in operating activities (in Dollars)", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow", "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r17", "r32", "r70", "r78", "r86", "r94", "r96", "r101", "r109", "r115", "r117", "r118", "r119", "r120", "r123", "r124", "r129", "r141", "r142", "r144", "r146", "r150", "r158", "r159", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r224", "r225", "r290", "r321" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedTotalLabel": "Net loss and comprehensive loss", "terseLabel": "Net loss", "verboseLabel": "Net loss (in Dollars)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement", "http://raphaelpharmaceuticalinccom/role/GeneralDetails", "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r117", "r118", "r119", "r120", "r125", "r126", "r130", "r133", "r141", "r142", "r144", "r146", "r290" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss applicable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently issued accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "(*) Cash acquired in the reverse recapitalization:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r22" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Total financial expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r1", "r66", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "terseLabel": "Total Payables to related party" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofrelatedpartybalancesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r141", "r142", "r144", "r146", "r290" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "negatedTotalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards (in Dollars)" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r62" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "GENERAL" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/General" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r92", "r296" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://raphaelpharmaceuticalinccom/role/ScheduleofothercurrentassetsTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets", "totalLabel": "Total" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet", "http://raphaelpharmaceuticalinccom/role/ScheduleofothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other current assets.", "label": "Other Current Assets [Text Block]", "terseLabel": "OTHER CURRENT ASSETS" } } }, "localname": "OtherCurrentAssetsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/OtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherGeneralExpense": { "auth_ref": [ "r21" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general expenses not normally included in Other Operating Costs and Expenses.", "label": "Other General Expense", "terseLabel": "Others" } } }, "localname": "OtherGeneralExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNotesPayable": { "auth_ref": [ "r1", "r66", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes payable classified as other.", "label": "Other Notes Payable", "terseLabel": "Payables to related party - Officers" } } }, "localname": "OtherNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofrelatedpartybalancesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForFees": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for fees classified as other.", "label": "Payments for Other Fees", "terseLabel": "Rambam research agreement paid" } } }, "localname": "PaymentsForFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance cost (in Dollars)" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r24" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r68", "r76", "r91" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ScheduleofothercurrentassetsTable": { "order": 2.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid Expense", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r25" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Receipt of a loan" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalAndContractServicesExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.", "label": "Professional and Contract Services Expense", "terseLabel": "Professional services" } } }, "localname": "ProfessionalAndContractServicesExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r79", "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional Fees", "terseLabel": "Consulting services" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofrelatedpartytransactionsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r86", "r94", "r96", "r105", "r109", "r115", "r123", "r124", "r141", "r142", "r144", "r146", "r150", "r158", "r159", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r214", "r217", "r218", "r224", "r225", "r264", "r290", "r294", "r295", "r307", "r321" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesApprovedEquityCapitalStructurePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of public utility's approved equity to capital, including debt and equity.", "label": "Public Utilities, Approved Equity Capital Structure, Percentage", "terseLabel": "Share capital percentage" } } }, "localname": "PublicUtilitiesApprovedEquityCapitalStructurePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ReceivablesFromBrokersDealersAndClearingOrganizations": { "auth_ref": [ "r64" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ScheduleofothercurrentassetsTable": { "order": 1.0, "parentTag": "us-gaap_OtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount receivable from broker-dealers and clearing organizations, including, but not limited to, securities failed-to-deliver, certain deposits for securities borrowed, open transactions, good faith and margin deposits, commissions and floor brokerage receivables.", "label": "Receivable from Broker-Dealer and Clearing Organization", "terseLabel": "Receivables from governmental authorities" } } }, "localname": "ReceivablesFromBrokersDealersAndClearingOrganizations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofothercurrentassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r184", "r238", "r239" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r84", "r238", "r239", "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party", "terseLabel": "Total general and administrative expenses" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofgeneralandadministrativeexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r184", "r238", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r236", "r237", "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTIES BALANCES AND TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r55", "r83", "r342" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost": { "auth_ref": [ "r82" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.", "label": "Research and Development Expense, Software (Excluding Acquired in Process Cost)", "terseLabel": "Total" } } }, "localname": "ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofresearchanddevelopmentexpensesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r5", "r50", "r74", "r273", "r274", "r296" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r85", "r112", "r113", "r114", "r116", "r122", "r124", "r151", "r190", "r191", "r192", "r204", "r205", "r222", "r270", "r272" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r18", "r80", "r160", "r161", "r162", "r166", "r167", "r168" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Total related party transactions" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ScheduleofrelatedpartytransactionsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyAgreementTermsMember": { "auth_ref": [ "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "Terms of the royalty agreement under research and development arrangements.", "label": "Royalty Agreement Terms [Member]", "terseLabel": "Royalties [Member]" } } }, "localname": "RoyaltyAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Total consideration for purchase (in Dollars)" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of other accounts payable and accrued expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/OtherAccountsPayableandAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred income taxes" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of net loss per share and the weighted average number of shares" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciling item between the statutory tax rate of the Company and the effective tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of income tax rate" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amounts of other current assets.", "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of other current assets" } } }, "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/OtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of related party transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/RelatedPartiesBalancesandTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r30" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based payment in exchange for services" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted shares (in Shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Share issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Exercise price per share (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r38", "r107" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r15", "r48", "r85", "r99", "r100", "r101", "r112", "r113", "r114", "r116", "r122", "r124", "r135", "r151", "r182", "r190", "r191", "r192", "r204", "r205", "r222", "r226", "r227", "r228", "r229", "r230", "r231", "r235", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/GeneralDetails", "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3", "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r112", "r113", "r114", "r135", "r247" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r2", "r3", "r48", "r49", "r50" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Issuance of common stock and warrants (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of common stock in exchange for services (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Effect of reverse recapitalization transaction (Notes 1a and 7b) (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Split combined each shares (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r15", "r48", "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common stock and warrants" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of common stock in exchange for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Effect of reverse recapitalization transaction (Notes 1a and 7b)" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionExercisePriceIncrease": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.", "label": "Stock Option, Exercise Price, Increase", "terseLabel": "Exercise price (in Dollars per share)" } } }, "localname": "StockOptionExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r3", "r6", "r7", "r44", "r296", "r310", "r318", "r330" ], "calculation": { "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedBalanceSheet", "http://raphaelpharmaceuticalinccom/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r54", "r108", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r182", "r221" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Share exchange common stock (in Shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse split, description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/GeneralDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r232", "r243" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r232", "r243" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r232", "r243" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ContingentLiabilitiesandCommitmentsDetails", "http://raphaelpharmaceuticalinccom/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r242", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Non cash supplement" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Common shares issued" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r41", "r42", "r43", "r136", "r137", "r138", "r139" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimate in preparation of financial statements" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Consideration amount (in Dollars)" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/StockoldersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r127", "r133" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares used in computing basic and diluted net loss per share (in Shares)", "verboseLabel": "Number of shares of common stock used in computing basic and diluted net loss per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement_Parentheticals", "http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable", "http://raphaelpharmaceuticalinccom/role/ScheduleofnetlosspershareandtheweightedaveragenumberofsharesTable_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r125", "r133" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares used in computing basic and diluted net loss per share (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://raphaelpharmaceuticalinccom/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.6)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r299": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r301": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r302": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r303": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r304": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r305": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r306": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56015-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=35710130&loc=d3e41645-110958", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.1)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 64 0001213900-23-043104-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-043104-xbrl.zip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